Synthetic Approaches to the Anticancer Agent Streptonigrin by McElroy, William Thomas
  
 
 
 
 
 
 
 
ABSTRACT 
 
Title of Dissertation: SYNTHETIC APPROACHES TO THE ANTICANCER 
AGENT STREPTONIGRIN 
 
William Thomas McElroy, Doctor of Philosophy, 2005 
 
Dissertation directed by: Professor Philip DeShong 
    Department of Chemistry 
 
 
 
     Pd-catalyzed coupling reactions have a central place in synthetic chemistry.  In 
particular, studies from the DeShong laboratory have demonstrated that 
aryltrialkoxysilanes, in the presence of Pd(0) and fluoride, are capable of aryl group 
transfer to a range of aryl halides and triflates and allylic benzoates.  The cross-coupling 
reaction represents an ideal opportunity to construct the tetracyclic core of the anticancer 
agent streptonigrin.  This strategy is highly convergent and readily amenable to the 
synthesis of analogues, and as such would constitute an improvement over previous total 
syntheses of this natural product. 
     A series of 4-bromopyridines (streptonigrin C ring precursors) were prepared, and 
their couplings with various arylsiloxanes (streptonigrin D ring precursors) examined.  
The coupling reaction generally tolerated the preparation of sterically demanding biaryls.  
The coupling of the 3-nitro-4-bromopyridine derivative was problematic, as 
dehalogenation was found to compete with arylation.  The use of nitro group surrogates 
and a variety of catalyst systems offered no improvement.  These results indicated the 
coupling reaction is highly sensitive to the electronic environment of bromopyridine. 
     The analogous biaryl coupling reaction employing an organoboron species was more 
effective and allowed for additional streptonigrin CD analogues to be prepared.  This 
reaction was found to be highly sensitive to the reaction conditions.  A fully 
functionalized C ring precursor (prepared in 10 synthetic operations) underwent Suzuki 
coupling with a fully functionalized D ring precursor (prepared in 3 steps) to give an 
adduct possessing the streptonigrin CD skeleton.  This species was elaborated to a 
precursor suitable for appendage to the AB ring component. 
     A streptonigrin A ring derivative has been prepared in 6 steps from resorcinol.  The 
functionalities present in this species are compatible with several possible strategies to 
prepare the ABCD framework of the natural product.  Results of a model study indicate 
that the coupling of an A ring aryl siloxane with the CD fragment (possessing a three-
carbon fragment in the form of an allylic benzoate) is viable approach to the natural 
product.  Further studies are warranted to evaluate the requisite annulation to prepare the 
B ring.   
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Introduction 
 
     The formation of carbon-carbon bonds continues to be the most crucial transformation 
in synthetic chemistry.  The development of new protocols for carbon-carbon bond 
construction, however, remains an area of active investigation.1  From an intellectual 
perspective, carbon-carbon bond formation poses the challenge of attaching two atoms 
with identical electronegativities.  Perhaps more significantly, the development of new 
methodologies in this arena often allows for the preparation of target molecules that are 
inaccessible by other means. 
     During the first half of the twentieth century, numerous strategies were developed for 
the attachment of two saturated, sp3 hybridized carbon atoms to one another.  There were 
few methods for the creation of carbon-carbon bonds in which one or both of the atoms 
were sp2 or sp hybridized.  The last fifty years have witnessed the invention of a number 
of new reactions that address this void.  A particularly significant finding has been that 
carbon atoms covalently bonded to transition metals behave as nucleophiles, and as such 
react with organic electrophiles (Eq. 1).  Although formally a substitution reaction, the 
mechanism and substrate restrictions of this reaction are different from those observed in 
an SN1 or SN2 process.  Importantly, the reaction allows for the coupling of sp2 and sp 
hybridized carbon atoms, which may be present in either partner.   
 
C M CX
X = I, Br, ClM = transition metal
C C+ (1)
 1
     One of the older, although still widely used, examples of this process involves the 
addition of a dialkyl or diaryl organocuprate to an alkyl halide, with concomitant loss of 
copper (Eq. 2).2  The organocuprate, or Gilman reagent, is in turn usually prepared upon 
treatment of an organohalide with an alkyl lithium, followed by CuI (or CuCN).  The 
reaction is of wide scope, and generally allows for sp, sp2, and sp3 hybridized carbons to 
be coupled. 
1) R-Li
2) CuI R' Cu R'
Li
(2)R' X
X R''
R' R''
 
     There are nevertheless several limitations of this reaction.  The strongly basic 
conditions required to generate the organocuprate make this operation incompatible with 
several functional groups.  Although the coupling step is tolerant of most functionalities, 
aldehydes notably may not be present, since they react faster than the alkyl halide.  The 
instability of the dialkylcuprate usually necessitates that a large excess of this reagent be 
employed.  Additionally, as presented in Eq. 2 only half of the starting R’ group is 
transferred from the Gilman reagent to the alkyl halide, although the development of 
higher order cuprates has addressed this issue.3 
     In response to these limitations, other methods for the cross-coupling of unsaturated 
centers have been explored.1  Of critical importance has been the discovery that ligand 
stabilized transition metals can be added in situ to a reaction mixture, and are capable of 
mediating the cross-coupling reaction between two organic partners.  This finding has led 
to an explosion in the number of methods available for carbon-carbon bond formation.  
Although each of these reactions possesses its own mechanistic nuances, many are 
fundamentally similar, and operate as outlined in Scheme 1.   
 2
     In the absence of the transition metal complex, organic species A and B are unreactive 
to each other.  However, upon the addition of a suitable metal complex (M, L = ligand), 
one of the two species interacts with the metal to generate a reactive intermediate, 
denoted A*.  This intermediate frequently possesses some type of bonding interaction 
between the metal and organic molecule, illustrated as the dashed line.  Association with 
the second organic reactant B converts it to its reactive state, denoted B*.  Finally, the 
metal mediates covalent bond formation between the two reactive species A* and B* to 
generate the A-B bond.    
Scheme 1 
A
B*
MLn
A*
MLn
A*
LnM A BB+
 
     In addition to requiring less reactive nucleophilic partners (than, for example, lithium 
dialkylcuprates) the use of transition metal complexes to control carbon-carbon bond 
formation offers several other advantages.  The metal complex frequently can be used 
catalytically, and in many instances can be recovered following the reaction.  
Additionally, the rational modification of the metal’s ligands can alter the chemo-, regio-, 
and stereochemical course of the reaction. 
     No other metal has been as widely studied for these and other synthetic purposes as 
palladium.4  The origin of applications involving this metal can be traced to the catalytic 
hydrogenation of olefins,5 and although numerous other metals have since been shown to 
catalyze the reaction, Pd continues to find widespread use in catalytic hydrogenations.  
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Similarly, the Wacker process6 (Eq. 3), first reported in 1959 as a method for the 
conversion of ethylene to acetaldehyde, remains a valuable method for the oxidation of  
olefins and is frequently used in the synthesis of complex targets.7  
H2C CH2
PdCl2
H2O H3C H
O
(3)
     
     The above reactions serve as a testament to Pd’s versatility: the metal is capable of 
catalyzing both the oxidation and reduction of carbon atoms.  More remarkable, however, 
is the ability of Pd complexes to mediate carbon-carbon bond formation.  Cross-coupling 
reactions involving Pd have proven to be highly valuable in the construction of 
biologically active targets.8  Several of these reactions deserve further comment.   
     One of the earliest cross-coupling strategies to be developed is the Heck reaction (Eq. 
4).9  This transformation involves the Pd-catalyzed addition of an olefin to an aryl or 
vinyl halide or triflate.  The alkene functionality is retained in the product, allowing for 
subsequent modification, and the reaction tolerates a wide variety of functional groups.  
Although the Heck coupling has been performed with a variety of olefins, it has been 
shown that the best alkene substrates for the reaction are those that possess an electron-
withdrawing group (EWG).  Presumably this group increases the electrophilicity of the β 
carbon of the α,β-unsaturated olefin and improves it susceptibility to nucleophilic attack 
by a transient organopalladium species.  The EWG also provides a regiochemical bias.  
The analogous Sonogashira reaction, in which a terminal alkyne rather than an alkene is 
employed, has also been reported (Eq. 5).10 
 4
MeO2C X
X = I, Br, Cl, OTf
Pd catalyst
Base
MeO2C
+ (4)
X
X = I, Br, Cl, OTf
Pd catalyst
Base
+ (5)H
MeO2C
MeO2C
     
     Perhaps the most significant development in the field has been the Pd-catalyzed cross-
coupling of aryl and vinyl halides and triflates with carbon atoms possessing an 
electropositive main group atom (EMG) (Eq. 6).  Some examples of these species 
include, but are not limited to, organoboranes, organostannanes, and organosilanes (vide 
infra).  These compounds can be viewed as weakly nucleophilic by virtue of the higher 
electronegativities of carbon relative to the EMG.  This reaction is frequently applied to 
systems in which the two carbon atoms to be coupled to each other are sp2 hybridized.   
 
   The cross-coupling of alkenyl and aryl partners makes possible the synthesis of 1,3-
 
X = I, Br, Cl, OTf
+
EMG = B, Sn, Si, etc.
Pd
(6)
X
EMG
 
  
butadiene, styrene, and biaryl derivatives, as depicted in Scheme 2 (X = I, Br, Cl, OTf). 
In terms of reactants and reaction products, this method resembles the organocuprate 
coupling previously discussed.  An important difference, however, is the attenuated 
reactivity of the species bearing the EMG atom relative to its organocuprate cousin.  This 
 5
limited reactivity allows for a myriad of functional groups to be present.  The two most 
well-studied reactions are the Stille11 and Suzuki-Miyaura12 couplings.    
 Scheme 2 
X (HO)2B
Pd catalyst
X
Me3Sn
X
(EtO)3Si
SnMe3
XPd catalyst
Pd catalyst
Pd catalyst
+
+ +
+
 
     An example of the Stille coupling13 is presented in Eq. 7.  Reaction of an organohalide 
(1) with an organostannane (2), in the presence of a catalytic amount of Pd(0) gives 
cross-coupled adduct 3.  The Sn atom usually possesses an aryl or alkenyl substituent that 
is to be transferred, and three alkyl groups, which are essentially non-transferable.  The 
reaction is of wide scope, as virtually all functional groups are tolerated, and has been 
performed with heteroaromatic coupling partners.  The generality of the method has 
allowed for its widespread use in natural products synthesis.14  However, a major 
limitation of the Stille coupling is the use and generation of toxic tin reagents.  
Additionally, the tin by-products formed during the reaction are often difficult to separate 
from the desired product.         
(7)
1 2 3
I
Bu3Sn+
85 %
PdCl2(MeCN)2
DMF
 6
     The Suzuki-Miyaura coupling is analogous to the Stille reaction but deploys a boronic 
acid (or boronic ester) in place of the organostannane.  An example15 is shown in Eq. 8.  
The Pd-catalyzed reaction of aryl halide 4 and phenylboronic acid gave adduct 5 in good 
yield.  The Suzuki-Miyaura reaction, like the Stille coupling, is generally tolerant to other 
functional groups and has also found widespread use in natural products chemistry.16  An 
advantage of the Suzuki-Miyaura coupling over the Stille reaction is that organoboranes 
are much less toxic than their organostannane counterparts, and the boron byproducts 
generated during the course of the reaction are easily removed after an aqueous wash.  
However, boronic acids are somewhat unstable, and can be difficult to purify.  This 
usually requires that this functionality be installed immediately prior to the coupling 
reaction.  The use of boronic esters addresses this issue since these compounds are easier 
to handle; however, they are in some instances less reactive than the parent boronic 
acids.17 
Br
O
MeO2C
O
MeO2C
(HO)2B
Pd(PPh3)4, NaOEt
Et2O, PhH
75 %
(8)
4 5
 
     More recently, the use of atoms other than tin or boron in the cross-coupling process 
has been described.  In particular aluminum, zirconium, and especially zinc have been 
shown to be viable alternatives to their tin and boron counterparts.  The use of such 
metals in cross-coupling reactions is generally referred to as the Negishi coupling,18 and 
an example is presented in Eq. 9.19  p-Iodoanisole and phenylzinc chloride, when treated 
with a catalyst prepared from Cl2Pd(PPh3)2 and DIBAL, reacted to afford cross-coupled 
 7
adduct 6 in high yield.  In general, the organometallic species present in Negishi 
couplings possess the advantage of being more reactive than organostannanes or 
organoboranes, and their use usually requires milder reaction conditions.  However, they 
are at times tedious to prepare, and lack the chemoselectivity possessed by tin and boron 
reagents. 
 
   The limitations associated with the above protocols, particularly the Stille and Suzuki 
structural motifs are accessible through the cross-coupling of organosilanes 
(Scheme 2), and the formation of styrene derivatives has been thoroughly examined.  
I
MeO
ClZn
Cl2Pd(PPh3)2
     DIBAL
87 %
MeO
6
(9)
  
couplings, have prompted the development of alternatives to these reactions.  
Importantly, organosilanes have been shown to undergo Pd-catalyzed coupling with 
organic halides and triflates. The cross-coupling of organosilanes, like those of 
organoboranes and organostannanes, is tolerant of most functional groups.  The silicon-
based couplings offer added benefits:  organosilanes are less toxic than organostannanes, 
and a major advantage relative to their organoboron counterparts is that the silanes can 
typically be purified by chromatography, and in some cases distillation.  Several research 
groups have been active in this area, and the development of silicon-based coupling 
strategies has recently been reviewed.20  The following discussion provides a brief 
overview. 
     Several 
 8
There are few examples of neutral alkenylsilanes undergoing coupling with aryl halides.  
For example, Westerlund21 has shown that aryl iodides possessing various substituents in 
the para position react with vinyltrimethylsilane, in the presence of a Pd catalyst, to give 
styrene derivatives (Eq. 10). 
 
e neutral silane to its “ate” complex (Eq. 11).22  This is typically accomplished in situ 
 
 
is(diethylamino)sulfonium difluoro(trimethyl)silicate (TASF), undergo Pd-catalyzed 
I
R = H, Me, OMe, NO2
         TEA
Me3Si
R51-60 %
(10)
R
Pd(OAc)2, PPh3
+
     Most Pd-catalyzed couplings of organosilanes, however, require prior conversion of 
th
upon treatment of the silane (7) with an appropriate nucleophile, which generates a 
pentacoordinate silicate species such as 8 (Eq. 11).  This complex is then capable or vinyl 
(or aryl) group transfer to Pd.  The natures of the R groups have a dramatic impact on the 
process, as these groups must be capable of withdrawing electron density from the silicon 
atom in 7, increasing its electrophilicity and favoring formation of 8. 
SiR3
7
SiR3
8
Nuc Pd(0)
(11)
Nuc X
     Hiyama23 has shown that alkenylfluorosilanes, when activated with
tr
coupling with a variety of aryl iodides (Eq. 12).  In most cases the fluorosilane may be 
prepared from treatment of its corresponding chlorosilane with copper fluoride.  This 
strategy is therefore limited by the availability of the precursor chlorosilanes, as well as 
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the necessity of the expensive, moisture sensitive TASF.  Additionally, in this case only 
aryl iodides, and not the more readily available bromides and chlorides, have been 
demonstrated to undergo the reaction. 
 
ents 
q. 13),24 with activation of the silane being accomplished through the addition of 
 
lkenylsilanols with aryl iodides (Eq. 14).25-27  Either TBAF or Ag2O28 can be employed 
I
R
2
[PdCl(allyl)]2, TASF alkyl
FMe Si+ (12)
alkyl
     A more general process makes use of alkenyldichlorosilanes as olefin transfer reag
(E
NaOH.  This reagent combination has been shown to undergo alkenyl group transfer to 
aryl bromides and chlorides, as well as iodides.  Again, the strategy is limited by the 
availability of the alkenylchlorosilane.  Additionally, the use of the highly nucleophilic 
and basic hydroxide ion makes this process incompatible with several functional groups.   
X Pd catalyst, NaOH alkyl
X = Br, Cl
R
Cl2MeSi+ (13)
alkyl
     Denmark has addressed some of these concerns through the coupling of 
a
as the activator, and the silanol may be prepared from the corresponding alkenyl bromide 
or iodide.  Importantly, the reaction proceeds with retention of alkene geometry, and both 
E and Z alkenyl groups have been transferred.  The reaction has recently been expanded 
to allow for the use of fluorosulfonate esters in place of iodides.29  In a related process, 
alkenylsilacyclobutanes30 have been shown to be competent in the Pd-catalyzed transfer 
of olefinic groups (vide infra). 
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      The 
xamined area since the biaryl motif accessible through this strategy is found in 
 
, 36 
q. 17), are suitable partners for Pd-catalyzed coupling with aryl iodides.  A few 
 
I
R
Pd(dba)2, TBAF
(14)n-C5H11
n-C5H11
e
Si+
HO
Me M
Pd-catalyzed coupling of aryl silanes with aryl halides also represents a well-
e
numerous natural products.31  Many of the developments in biaryl formation parallel 
those described for the synthesis of styrene derivatives.  For instance, Hiyama32 has used 
arylfluorosilanes in couplings with aryl iodides (Eq. 15).  The reaction was found to be 
tolerant of both electron donating and electron withdrawing groups present on either 
partner.  A more useful variation of this reaction utilizes aryldichlorosilanes as the 
coupling partners,33 as this allows for reaction with more readily available aryl bromides.   
I
+
[PdCl(allyl)]2, KF
(15)
R'
R
R
alkylF2Si
R'
     Denmark has demonstrated that arylsilacyclobutanes34 (Eq. 16), as well as silanols35
(E
examples of aryl bromides undergoing the reaction have also been reported.35, 36 
MeO
Si R
MeO
[PdCl(allyl)]2, TBAF
(16)
R
SiMe2OH
+
R'
I
Pd(PPh3)4, Ag2O
R
R'
(17)
Cl
I
R
+
 11
     As an alternative to the Stille and Suzuki-Miyaura couplings, each of the reactions 
oupling 
 
   Recent findings have addressed this issue.  It has been shown that aryltrialkoxysilanes, 
described above has merit.  Nevertheless, there a number of limitations associated with 
these and other silicon-based strategies.  Many of the requisite organosilanes require 
several synthetic operations to prepare.  Furthermore, several of the described processes 
are compatible with only aryl iodides, and not bromides or chlorides.  From a practical 
standpoint, the ideal coupling technology would be address both of these issues.  
     The DeShong group has for some time been pursuing silicon-based cross-c
strategies.  Initial studies focused on the use of tetrabutylammonium 
triphenyldifluorosilicate (TBAT, 9) as a phenylating agent.37, 38  TBAT is an air- and 
moisture-stable crystalline salt which is readily prepared from triphenylsilanol.39  It has 
been shown that TBAT undergoes Pd-catalyzed cross-coupling with a variety of aryl 
iodides and electron-deficient aryl bromides and triflates.  An example is presented in Eq. 
18.  The use of TBAT is limited, however, by the fact that only unsubstituted phenyl 
groups may be transferred.   
Si
F
Ph
Ph
9
MeO
I
[PdCl(allyl)]2 MeO
Ph
97 %
(18)
F
Ph
Bu4N
  
upon exposure to TBAF, are presumably converted to their corresponding fluorosilicate 
complexes (Scheme 3, X = I, Br).  These species, in the presence of a catalytic amount of 
Pd(0), undergo aryl group transfer to a range of aryl iodides and bromides.40-42    
 12
Scheme 3 
Si(OEt)3
R TBAF, Pd(0)
Si(OEt)3
R
FX
R'
R
R'
 
     Much effort has been devoted to determine the scope and limitations of the above 
process.  It has been found that the reaction is generally tolerant of both electron donating 
and electron withdrawing groups, which may be present in either partner.  An exception, 
however, regards the coupling of arylsiloxanes that bear a heteroatom in the position 
ortho to silicon on the aromatic ring.  These species have been found to undergo rapid 
protodesilylation under the reaction conditions (Scheme 4).43, 44   
Scheme 4 
Si(OEt)3
OMe
Ar-I, TBAF
   Pd(0)
H
OMe
Ar
OMe
 
     The proposed catalytic cycle38 for the cross-coupling reaction is presented in Figure 1.  
Oxidative addition of a Pd(0) species into the carbon-halogen bond of the aryl halide 
generates 10, which then undergoes transmetallation with the silicate to form 11.  
Reductive elimination yields the cross-coupled product and regenerates the Pd(0) 
catalyst.  A similar catalytic cycle has been proposed for the Stille11 and Suzuki12 
couplings. 
 
 13
LnPd
(0)
X
X = I, Br, Cl, OTf
R
LnPd
R
X
Si(OEt)3
R'
F
LnPd
R
R'
1011
X-Si(OEt)3
R
R'
F
 
Figure 1.  Proposed catalytic cycle for the Pd-catalyzed cross-coupling of aryl halides 
with aryltrialkoxyfluorosilicates.      
 
 
     Very recently the siloxane coupling technology has been extended to allow for the 
preparation of biaryls in which one or both of the rings are heteroaromatic.44  These 
explorations have obvious importance since many pharmaceutical agents possess 
heteroaromatic ring systems.  For example, 3-bromoquinoline underwent cross-coupling 
with PhSi(OMe)3 to deliver adduct 12 in 60% yield (Eq. 19).  The framework present in 
12 resembles that found in the anticancer agent camptothecin (13),45 and it is anticipated 
that this approach to camptothecin and its analogues would be successful. 
 
 
 14
NTBAF, Pd(OAc)2, PPh3
DMF
60 % N
(19)
12
N
N
O
O
O
HO
(S)-camptothecin (13)
Br
(MeO)3Si
Pd-catalyzed cross-coupling
 
     The Pd-catalyzed cross-coupling of aryltrialkoxysilanes and aryl halides to form 
unsymmetrical biaryls has been a fruitful area of research.  No less significant, though, 
has been the development of the coupling strategy as a method for allylic arylation.37, 46, 47  
While the Pd-catalyzed addition of stabilized nucleophiles (i.e., malonates, azides) to 
allylic alcohol derivatives has been known for some time,48 the addition of aryl groups to 
these systems has remained less explored.  The DeShong lab has shown that 
aryltrialkoxysilanes, upon treatment with fluoride and catalytic Pd(0), are capable of aryl 
group transfer to allylic carbonates and benzoates (Eq. 20).  For example, the reaction of 
allylic benzoate 14 with PhSi(OEt)3 gave a 95% yield of adduct 15.46  
OBz
Si(OEt)3
TBAF, Pd(dba)2
THF
95 %
(20)
14 15
 15
Scheme 5 
OCO2Et
NHCO2Et
Si(OEt)3O
O
TBAF, Pd(dba)2
        THF
NHCO2Et
NHCO2Et
O
O
O
O
67 % (ratio 18/19 = 1:1)
16
17
18 19
+
NH
O
O
OH
HO
O
 
     This methodology is currently being developed for the synthesis of more complex 
systems.  For example, arylation of allylic carbonate 16 with siloxane 17 afforded a 67% 
yield of regioisomers 18 and 19 in a 1:1 ratio (Scheme 5).47  The regio- and 
stereochemical aspects of this and related transformations have been discussed.37, 46, 47  
Efforts are currently underway to apply this technology in a regio- and stereoselective 
manner to the synthesis of biological targets.49  
     As described above, Pd-catalyzed cross-coupling reactions represent an enormously 
powerful synthetic method for complex natural product synthesis.  Our interest in these 
reactions stems from the fact that they may be used in the formation of highly 
functionalized molecules.  We were particularly interested in further exploring the Pd-
catalyzed coupling of aryltrialkoxysilanes with aryl halides to form heteroaromatic 
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systems.  Since it incorporates a dense array of functionality on three aromatic rings, the 
anticancer agent streptonigrin (20) represents an attractive target.  Our synthetic strategy 
is to first form the CD biaryl using a Pd-catalyzed coupling of a suitably functionalized 4-
bromopyridine and appropriately substituted D ring siloxane.  Appendage of the 
quinoline moiety would likewise be accomplished through a second coupling with an 
suitably functionalized quinoline siloxane.  The approach is described in detail in Scheme 
10 (Results and Discussion).  What follows is a description of streptonigrin’s biological 
activity and relevant synthetic studies.  Several reviews regarding the isolation, structure 
determination, biological activity, and synthetic endeavors toward streptonigrin have 
appeared.50-55  
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     The ability of Streptomyces bacteria to produce metabolites that possess a range of 
biological activities is well known.56  It was armed with this knowledge that in 1959 Rao 
and Cullen described the isolation of a dark brown, crystalline solid from Streptomyces 
flocculus.57  The same compound was later isolated from S. rufochromycin and S. 
echinatus58 and Actinomyces albus var bruneomycini.59  Interest in the newly isolated 
metabolite was heightened by reports of potent anticancer activity.  Thus, following a 
series of spectroscopic and degradative studies,60 the structure of streptonigrin was 
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determined (20), and assignment was subsequently confirmed through X-ray 
crystallography.61  Recently the proton, carbon, and nitrogen resonances in the respective 
NMR spectra have been assigned.62, 63   
     It has been shown that the AB and C ring systems of 20 are oriented coplanar to one 
another (at least in the solid state), while the C and D rings are orthogonal.61  This latter 
observation is to be expected, given the sterically congested nature of the CD ring 
juncture.  Thus, streptonigrin may be found as either of two atrope isomers, with hindered 
rotation about the CD bond expected (Figure 2).  Indeed, naturally occurring streptonigrin 
is optically active,64 and an M configuration has recently been assigned.65  The barrier to 
interconversion is at present unknown.   
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Figure 2.  Atrope isomers of streptonigrin. 
 
     Streptonigrin exhibits potent antiviral, antibiotic and anticancer activities (vide infra).  
It is the last property that has made this natural product the subject of numerous 
biological and medicinal studies.  The compound was ultimately advanced to clinical 
trials; however, toxic side effects resulted in the termination of these studies.66  
Nevertheless, the use of streptonigrin in combination chemotherapy suggests that this 
compound (or analogues) may be of future clinical use.67-69 
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     Several studies have explored streptonigrin’s mode of action, and the ability of 20 to 
induce apoptosis has been recently been reported.70, 71  Additionally, the cytotoxic 
properties of streptonigrin have been attributed to depletion of NADH/NADPH,72, 73 the 
disruption of oxidative phosphorylation,74, 75 and single-strand DNA cleavage.76-79 The 
last property has been the most thoroughly studied. 
     The quinoline-5,8-dione is a recurring structural feature in several agents known to 
possess antitumor properties.80  It has been demonstrated that the quinone functionality of 
streptonigrin is capable of accepting hydrogen atoms from NADH to form a reduced (21) 
or semireduced species.81  Subsequent production of radicals (hydroxide or superoxide), 
in a process that involves oxygen and metal ions, is postulated to be the direct cause of 
DNA damage.77, 79, 81-85  Little is known about this event, but what is established is that 
streptonigrin itself interacts only weakly with DNA, but when in its reduced form or in 
presence of metal ions this interaction is magnified significantly.86-92 
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     Several structure-activity-relation (SAR) studies have been reported.55  The minimum 
functionalities required for biological activity are the A ring quinone, quinoline and 
pyridine nitrogen atoms, and C-ring carboxylic acid.  The modification of peripheral 
functional groups on the A ring affects the biological activity, as these groups presumably 
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     The biogenesis of streptonigrin has been established.93  Gould has elegantly 
determined through feeding experiments that streptonigrin is formulated in S. flocculus 
through a convergent pathway involving condensation of quinoline acid 22 with 
tryptophan derivative 23.  These pieces are in turn derived from anthranilic acid 24 and 
amino anthranilic acid 25.  Each of the anthranilic acids is obtained through condensation 
of phosphoenolpyruvate 26 with erythrose-4-phosphate 27.  Interestingly, 26 and 27 both 
originate from glucose metabolism. 
 
      The roles of the C ring methyl and amino groups, as well as the entire D ring, are 
unclear.  Analogues lacking each of each of these functionalities show somewhat 
diminished activity relative to the parent compound.  The fact that these analogues devoid 
of the D ring exhibit attenuated activity relative to the parent compound is significant 
since this structural feature confers optical activity upon the molecule.   
Figure 3.  Possible coordination event of 21 with a metal ion. 
 
influence the reduction potential of the quinone.  These findings, in conjunction with the 
observation that metal ions are required for biological activity, have led to the hypothesis 
that the ring nitrogen atoms and carboxylate group of 21 exhibit coordination with metal 
ions, with the resulting species responsible for free radical production (Figure 3).   
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igure 4.  Proposed biosynthesis of streptonigrin. 
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     In addition to displaying potent biological activity, streptonigrin represents a 
formidable synthetic challenge, as both acid and base sensitive functional groups are 
present.  The pyridine ring is highly functionalized, and the CD ring juncture is extremely 
congested.  Nevertheless, three total syntheses have been reported.     
     Weinreb94 reported the first total synthesis, with the key element of the approach 
being construction of the C ring through a hetero Diels-Alder reaction of diene 28 with 
dienophile precursor 29 (Scheme 6).  This resulted in the formation of a 3:1 ratio of the 
desired (30) to undesired (31) regioisomeric products.  The cycloaddition was plagued by 
incomplete conversion, and the 56% yield reported was obtained after one recycle of 
unreacted starting material.  Elaboration of 30 to phosphonate ester 32 was achieved after 
several steps.  This compound underwent Horner-Wadsworth-Emmons condensation 
with aldehyde 33 to afford enone 34 in good yield.  Reduction of the nitro group resulted 
in spontaneous conversion to the corresponding quinoline, thus establishing the 
tetracyclic core of the target.  This compound was converted to the natural product in 6 
steps.  Although imaginative, the synthesis is hampered by the number of steps and low 
overall yield.  Additionally, the key imino Diels-Alder reaction proceeds in only modest 
yield and regioselectivity. 
 
 
 
 
 
 
 22
Scheme 6 
 
     The Kende  synthesis allows for a much higher overall yield (1.3% to 0.013%) and 
fewer steps (Scheme 7).  In this case, the CD ring system was efficiently prepared 
through condensation of amino ketone 35 with methyl acetoactetate to afford pyridone 
36.  After some manipulations, pyridone 36 was converted to methyl ketone 37, which 
underwent cyclization with amino imine 38 to deliver quinoline 39 in high yield.  
Although the core of streptonigrin may be rapidly accessed using this pathway, 39 
requires 11 more steps to be converted to advanced intermediate 40, constituting a formal 
total synthesis of the natural product.  Most of these steps involve A ring functional group 
manipulations.  The synthesis is almost entirely linear and provided little opportunity to 
construct streptonigrin analogues that possess variable AB ring substituents.    
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     The most recent formal synthesis has been reported by Boger (Scheme 8).96  Th
described route relies on two successive imino Diels-Alder reactions to prepare the C ring 
of the natural product.  Thus, thioimidate 41 (prepared in four steps from 6-
methoxyquinoline) underwent Diels-Alder cycloaddition with tetrazine 42 to afford 
adduct 43 as a single regioisomer.  The second cycloaddition took place between 43 and 
enamine 44 to yield a 2.8:1 mixture of regioisomeric Diels-Alder adducts in a combined 
yield of 65%.  The regioselectivity in this process is comparable to that reported by 
Weinreb in his construction of the C ring.  Ultimately, the desired adduct 45 was 
elaborated to advanced intermediate 46, which had been previously prepared by Weinreb.   
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     The Boger strategy is attractive since the entire AB ring is constructed prior to 
attachment to the C ring.  Thus, the approach readily lends itself to the formation of 
nonnatural analogues.  One limitation, however, in the late stage conversion of the 
pyridine ring C-5 methyl ester in 45 to an amino group, as this requires the two methyl 
s of intermediate 45 to be differentiated. 
     The ideal synthetic approach to streptonigrin would allow for the efficient 
construction of the parent compound as well as a variety of analogues.  Several research 
ester
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groups have been actively pursuing a synthetic route to 20 that addresses the concerns 
 
 
 
 
  
 similar approach which utilizes an Ullmann coupling has also been reported.98 
present in the three total syntheses.  In this regard, Pd-catalyzed cross-coupling reactions
are uniquely suited to the synthesis of streptonigrin for several reasons.  First, the AB, C, 
and D rings may be independently prepared and variably functionalized prior to being 
coupled to each other, allowing for maximum convergence.  Second, many of the 
coupling reactions are tolerant to a variety of functional groups, thus minimizing 
protecting group strategies.  Finally, a wide variety of Pd catalysts, possessing varying 
reactivities, have been developed.  Several groups have engaged in the use of Pd-
catalyzed reactions in the total synthesis of streptonigrin and analogues.54     A major
concern to be addressed in formation of the CD ring system is the sterically congested 
nature of the biaryl bond.  Formation of this bond requires the use of sterically hindered, 
and thus presumably less reactive, coupling partners.  The most significant results to date
have been reported by Queguiner,97  who showed that 4-bromopyridine 48 underwent Pd-
catalyzed coupling with boronic acid 49 to afford biaryl 50 in 80% yield (Eq. 21).  The
nitro group was found to be essential in this process, as analogs of 48 that possessed a 
free amine or carbamate in place of the nitro functionality were shown to be unreactive.
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     Similarly, Hozapfel99 reported that the reaction of 4-chloropyridine 51 with boronic 
ester 52 afforded the cross-coupled product 53 in 80% yield (Eq. 22).  It is significant that 
the pyridyl chloride was sufficiently reactive in this process, as most Suzuki couplings 
require the use of the more reactive bromides or iodides.  The ability to prepare more 
hindered derivatives of 51 has yet to be reported by these authors.  
 
     Several groups have also explored the use of Pd-catalyzed methods to prepare ABC 
analogues of streptonigrin.  Queguiner100 has demonstrated that the Stille coupling of 
quinoline stannane 55 with pyridyl triflate 54 gave the expected product in 68% yield 
(Eq. 23).  Dimethoxy arene 56 could then be oxidized to its corresponding quinone.  
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     Harding101 has developed an elegant approach to ABC analogues of streptonigrin 
(Scheme 9).  Quinoline N-oxide 57 was converted to 2-iodoquinoline 58 via the 
 
     
66 
could be prepared in high yield using this protocol (Eq. 24), although the use of a 5-
intermediate chloroquinoline.  Nitration, followed by Stille coupling with pyridyl 
stannane 60 gave biaryl 61 in good yield.  Oxidation of the pyridine methyl group to its 
acid was accomplished upon treatment with SeO2; the acid was subsequently converted to 
its methyl ester.  After reduction of nitroquinoline 62, the quinoline-5,8-dione 
functionality was obtained upon reaction with Fremy’s salt.     
   Scheme 9  
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Finally, it has recently been reported that 2-chloroquinoline 65 underwent couplings 
with a variety of organoboranes and organostannanes.102  Most significantly, adduct 
 28
methyl pyridine derivative led to a marked decrease in yield.  It is interesting to note that 
the quinone functionality did not adversely affect the coupling reaction.  
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Results and Discussion 
Synthesis of the Streptonigrin CD Biaryl 
 
     Our retrosynthetic analysis for streptonigrin (20) is depicted in Scheme 10.  The 
tetracyclic core was to be established through the Pd-catalyzed coupling of quinoline 
siloxane 67 with 2-bromopyridine 68.  Conversion to the natural product would then be 
accomplished upon oxidation of the A ring to its p-quinone and global deprotection.  2-
Bromopyridine 68 would in turn to be prepared from biaryl 69.  This strategy would 
require the development of methods for the selective deprotection of the C-2 methyl ether 
of the pyridine ring, while the C-6 methyl group of pyridine 69 could be converted to a 
benzylic alcohol through application of the well-known pyridine N-oxide 
rearrangement.103  Further oxidation to the carboxylic acid would establish the f
69 was envisaged as the product of a Pd-
amenable to the synthesis of highly functionalized (and hindered) biaryls, as well as 
tolerant of the MOM ether ortho to a silicon-based functional group as in 71 (see Scheme 
4). 
catalyzed coupling of 4-bromopyridine 70 and aryl siloxane 71.  Successful 
implementation of this strategy would require the development of coupling conditions 
group found in the natural product.  Biaryl 
unctional 
31
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     The aforementioned coupling reaction to form the CD biaryl presents a major 
lop an approach to C ring coupling precursors 
at was amenable to the preparation of analogues, in order that the steric and electronic 
mplished as shown in Scheme 12.  Condensation of ethyl 2-methylacetoacetate and 
ammonium hydroxide gave enamine 74.  The use bentonite K-10 clay as a solid support 
allowed this reaction to be performed under mild conditions.106  Base-promoted reaction 
of 74 with diethyl methylmalonate afforded methyl pyridone 72a104 in 69% yield. 
  
     
synthetic challenge. We decided to deve
th
factors that influence the coupling reaction be investigated in a systematic manner 
(Scheme 11).  The synthetic precursors for the study were to be 4-hydroxypyridones (72), 
as it was believed that the C-4 hydroxyl group and C-2 carbonyl of 72 could be 
independently manipulated.  The pyridone would be prepared from condensation of 
amino ester 74 and diethyl malonate, or a derivative thereof (73).104, 105  An attractive 
element of this strategy is that the C-3 substituent of pyridone 72 presents the opportunity 
for diversification, since the identity of this group may be easily controlled at the 
malonate stage (73). 
Scheme 11 
 
     The preparation of a series of pyridones in which the C-3 substituent was varied was 
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 Scheme 12 
 
     Ester pyridone 72b was obtained in 61% yield upon condensation of enamine 74 with 
diethyl malonate.  The ethyl ester was easily removed upon hydrolysis of 72b followed 
by acid-promoted decarboxylation to give pyridone 72c, which possesses a hydrogen at 
C-3.      
     Although not part of our retrosynthetic plan, the coupling reactions of pyridyl triflates 
derived from 72a were briefly investigated (Scheme 13).  Thus, reaction of 72a under 
standard triflating conditions gave a mixture of mono-triflate 75 and bis-triflate 76, 
obtained in 38 and 41% yield, respectively.  Attempted couplings of 75 and 76 failed to 
give the desired adducts, due to facile hydrolyses of the fluorosulfonate ester 
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functionalities.  Accordingly, no attempt was made to improve the selectivity of triflate 
formation, and triflates were excluded from further studies. 
Scheme 13 
 
     Hydroxypyridone 72a was converted to bromopyridone 77 upon treatment with neat 
POBr3, as previously reported (Scheme 14).   The cross-coupling of 77 with TBAT, as 
well as PhSi(OMe)
Tf2O, DMAP
       py NTfO
CH3H3C
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104
nged.  The failure of this compound to undergo coupling is not 
surprising in consideration of the fact that previously reported couplings of 4-
halopyridones have required prior protection of the N-H proton.107  Accordingly, 
pyridones w
 
    The reaction of pyridone 77 with MeI using Ag2CO3 as the base gave pyridine 78 in 
quantitative yield, providing a species with which to investigate the coupling reaction 
(vide infra).  Notably, the attempted protection of the pyridine as a benzyl ether or 
methoxymethyl ether proved unsuccessful. 
3, was investigated.  Under all conditions the starting bromopyridone 
was recovered uncha
ere excluded from further coupling studies.   
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        POBr3
H
NO CH3 MeI, Ag2CO3
quant.
NMeO
CHH C
CH3HNO CH3
60 %
Br
CH3H3C
Br
33
OH
CH3H3C PhH
72a 77 78
 34
     The analogous replacement of the C-4 hydroxyl group of 72c with a bromine 
bstituent proved to be problematic, due in part to competitive bromination at C-2 
(Scheme 15).  After significant experi  was found that reaction of 72c with 
.  
 
 
   The cross-coupling reactions of bromopyridines 78 and 80 were expected to provide 
uired for streptonigrin through a Curtius rearrangement.  Thus, the synthesis of 
(presumed) poor solubility of the desired product. 
su
mentation, it
0.70 equiv POBr3 using DMF as the solvent led reproducibly to bromopyridone 79
Although the bromopyridone could be purified, it was found more convenient to carry the 
crude material through the next step.  Thus, methylation of the crude mixture gave
pyridine 80 in 37% isolated yield over two steps. 
Scheme 15 
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information regarding steric effects in the coupling process.  The cross-coupling of 82, 
though, would present an opportunity examine the influence of electronic factors.  More 
significantly, the ester functionality of 82 could in the future be converted to the amino 
group req
82 emerged as the next challenge.  
     Much to our surprise, treatment of 72b with POBr3 gave not the expected 
bromopyridone 81, but rather acid bromide 83 (Scheme 16).  A variety of brominating 
reagents and reaction conditions were examined in an effort to prepare 81 to no avail.  
The regioselectivity issues of the bromination reaction were compounded by the 
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 Scheme 16 
 
     Tribromide 83 did, however, prove useful.  Conversion of 83 to its methyl ester 84 
proceeded smoothly, allowing for an investigation into whether 2,4-dibromopyridine 84 
would undergo regioselective Pd-catalyzed cross-coupling.  Under a variety of coupling 
conditions, however, complex mixtures of products were obtained, and this strategy was 
not pursued further.108   
 
ondensation of ethyl 2-methylacetoacetate with benzylamine gave enamine 85 in 73% 
he hydroxyl group proved to be unreactive.   
  
     It was hoped that the protection of the N-H proton of 72b prior to bromination would 
improve the regioselectivity of the reaction, as well as the solubility of the desired 
product.  Accordingly, N-benzyl pyridone 87 was prepared as described in Scheme 17. 
C
yield.  Acylation with ethyl chloromalonate,109 followed by base induced ring closure 
delivered the desired N-benzyl pyridone 87.  Numerous attempts to replace the hydroxyl 
group of 87 with a bromine substituent were unsuccessful.  The ethyl ester was found to 
be labile under the reaction conditions, and t
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     The 
tors:  
ould allow for information regarding electronic effects in the coupling process to be 
 above, the nitro group would allow for an immediate 
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synthesis of bromopyridine 82 was clearly problematic, and the preparation of a 
more accessible species was explored.  Our initial interest in 82 had rested on two fac
first, the compound contains an electron-withdrawing group at the C-3 position, which 
w
obtained; second, the ester substituent could be ultimately be converted to an amino 
group required for the synthesis of streptonigrin.  Since nitropyridine 88 possesses both 
of these attributes, it represented a suitable alternative to 82 and became the next 
synthetic target.       
     Gratifyingly, pyridine 88 was obtained in near quantitative yield upon nitration of 
pyridine 80 (Scheme 18).  As stated
investigation into the electronic factors that influence the coupling reaction.  
Additionally, this substituent was to serve as a gateway to several other nitrogen 
containing functional groups, as 88 was readily reduced to the corresponding amine 89, 
which could then be protected in a variety of manners.   
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Scheme 18 
 
 
onducted at 80 °C with DMF as the solvent.  The coupling of pyridine 80 was 
ated) pyridine.  This result was somewhat surprising since it had 
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     With several 4-bromopyridine derivatives in hand, an investigation into their 
reactivities in the cross-coupling process was undertaken (Table 1).  Coupling reactions 
were performed under identical conditions employing 20 mole % Pd(OAc)2 and 40 mole
% PPh3.  Two equivalents of aryl siloxane and TBAF were used, and all reactions were 
c
investigated first, since this is the least sterically hindered of the bromopyridine series.  
The Pd-catalyzed reaction of 80 and PhSi(OMe)3 gave an excellent yield of the expected 
adduct (Table 1, entry 1).  However, the reaction of 80 with o-methyl siloxane 90110 gave 
only a 10% yield of the desired product (entry 2);  the remainder of the mass balance was 
reduced (hydrodebromin
previously been shown that siloxane 90 underwent coupling with bromobenzene in good 
yield.111  
     In order to further assess the steric tolerances of the coupling reaction, the coupling of 
trimethylbromopyridine 78 was examined.  The Pd-catalyzed reaction of 78 and 
PhSi(OMe)3 gave an 89% yield of the coupled adduct 91, while reaction of 78 and o-
methyl siloxane 90 provided only 10% of the desired biaryl product (92) (entries 3 and 4, 
respectively).  These results are similar to those obtained with bromopyridine 80, and 
demonstrate that ortho-disubstituted bromopyridines are suitable coupling partners.   
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NMeO CH3
R
(OAc)2, PPh3
NMeO
Ar
CH3
CH3
R
Entry R Ar-Si(OR')3 yield (%)
H, 80
H, 80
PhSi(OMe)3
PhSi(OMe)3
Si(OEt)3
CH3
97
10a
Me, 78
Si(OEt)3
O
89
NH2, 89 PhSi(OMe)3 0b
c
TBAF
DMF
1
2
3
6
90
93
Pd
Br
CH3
+ Ar-Si(OR')3
Me, 78
Me, 78
CH3
Si(OEt)3
O
10a
61
4
5
90
 
NHBOC, 96 PhSi(OMe)3 0d
NO2, 88 PhSi(OMe)3 36a
N3, 94 PhSi(OMe)3 0
NHAc, 95 PhSi(OMe)3 0a
7
8
9
10
athe remainder of the mass balance was reduced bromopyridine.  bthe starting pyridyl bromide was 
recovered unchanged.  cthe reaction gave only residual tar.  dthe BOC group was cleaved
T
si
able 1.  Cross-coupling reactions of 4-bromopyridine derivatives with various 
loxanes.  
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     The reaction of bromopyridine 78 enedioxy siloxane 93112 gave a 61% 
   The couplings of 4-bromopyridines possessing various nitrogen containing 
ti s was investigated.        
 with methyl
yield of coupled product (entry 5), indicating that the coupling additionally allows for 
electron-rich arylsiloxanes to be employed.  This was a significant finding since the 
substitution pattern found in siloxane 93 resembles the D ring of streptonigrin. 
  
substituents in the C-3 position allowed for an investigation into the electronic factors 
that govern the reaction.  Analogues containing the amino (entry 6), azido (entry 7), and 
protected amino (entries 8 and 9) functionalities at C-3 failed to yield coupled adduct 
upon reaction with PhSi(OMe)3.  However, reaction of nitropyridine 88 and PhSi(OMe)3 
gave a 36% yield of the desired product (97, entry 10), as well as 36% of reduced 
pyridine 98 (vide infra). 
     The fact that nitropyridine 88 underwent successful coupling (albeit with a simple 
arylsiloxane) was a pivotal result as it validated our overall synthetic strategy for the 
preparation of streptonigrin.  The low yield observed in the reaction was disappointing, 
but it was hoped that the coupling with more functionalized arylsiloxanes would provide 
more satisfactory results.  Thus, the coupling of nitropyridine 88 with siloxane 
deriva ve
     Siloxane 102 was prepared as outlined in Scheme 19.  Dakin oxidation of 
benzaldehyde 99 gave phenol 100 in good yield,113 which was then converted to its 
MOM ether 101.  In addition to protecting the phenol, the MOM group was to be 
employed in a directed metallation to prepare siloxane 102.43  In the event, treatment of 
101 with BuLi followed by trapping of the organolithium with Si(OEt)4 provided 
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siloxane 102 in 25% yield.  The yield for this reaction was somewhat less than expected 
based on previous results. 
Scheme 19 
     Veritrole siloxane 104 was obtained as described in Scheme 20.  Selective of veritrol 
was accomplished using NBS and bentonite K-10 clay as a solid support.114  Convers
of bromide 103 to its organomagnesium derivative, followed by reaction with Si(OEt)
gave siloxane 104 in 31% yield.  
Scheme 20 
     Results of siloxane-based coupling reactions between bromopyridine 88
streptonigrin D ring analogues are presented in Table 2.  The reaction of 88 with
PhSi(OMe)3 gave a 36% yield of the coupled product and 36% of reduced pyridine 
 
ion 
4 
 
 and 
 
96 
104 
sulted in the formation of 21% coupled adduct, along with 17% of reduced 
CHO
OMe
OMe
H2O2, B(OH)3
     H2SO4
70 %
OH
OMe
OMe
1) NaH, DMF
2) MOM-Cl
100 %
OMOM
OMe
OMe
1) BuLi, TMEDA
          Et2O
2) Si(OEt)4
25 %
OMOM
OMe
OMe
Si(OEt)3
THF
99 100
101 102
OMe
OMe
NBS
bentonite K-10
OMe
OMe
Br 1) Mg, THF
2) Si(OEt)4, THF
OMe
OMe
Si(OEt)3
91 %
31 %
103 104
(Table 2, entry 1), as previously stated.  The reaction of 88 with veritrole siloxane 
(entry 2) re
 41
pyridine 98.  Although the yields obtained using this siloxane are slightly lower than with 
PhSi(OMe)3, the ratios of coupled to reduced product are comparable.  Reaction of 
bromopyridine 88 with siloxane 102, using 20 mole % catalyst, resulted in the exclusive 
formation of the reduced pyridine 98 (entry 3).  This was not unexpected given the 
 the ortho position to undergo Pd-catalyzed couplings. 
 
previous observation that aryl siloxanes that possess an oxygen atom ortho to silicon 
undergo rapid protodesilylation under the reaction conditions.  In the absence of a 
competent coupling partner, 88 would then be expected to undergo reduction.  It was 
surprising that the even when a stoichiometric amount of Pd reagent111 was employed for 
the coupling of bromopyridine 88 and siloxane 102 reduced pyridine 98 was the sole 
reaction product (entry 4).  This result underscores the reluctance of aryl siloxanes 
possessing heteroatoms in
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NO2N
MeO CH3
CH3
Br
Ar-Si(OEt)3, TBAF
Pd(
NMeO CH3 NMeO CH3
 
Table 2.  Cross-coupling reactions of bromopyridine 88 with various siloxanes. 
OAc)2, PPh3
O2N CH3
OMe
-
-
Si(OEt)3
OMe
OMe
21
O2N CH3
36
entry
1a
2a
a
4b
Yield 98 (%)
c
only product observedc
+
17
athe c
Pd (O
88 98
104
Ar H
OMe
OMe
M
102
Ar-Si(OEt)3
Yield of coupled
   product  (%)
PhSi(OEt)3 36
OMe
OMOM
Si(OEt)3
3 only product observed
102
OMO
Si(OEt)3
oupling was performed using 20 mole % Pd(OAc)2.  
bthe coupling was performed using 100 mole % 
Ac)2.  
cthe product composition was estimated by crude NMR.
 
 
     It is well known that the nature of the Pd catalyst and its ligands have a dramatic effect 
on cross-coupling reactions, and alternative catalyst systems were examined in an effort 
to improve the ratio of coupled to reduced products with regard to coupling reactions of 
bromopyridine 88 (Table 3).  Veritrole siloxane 104 was selected as the coupling partner 
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for this catalyst study, as the substitution pattern found on the aryl ring resembles that of 
streptonigrin’s D ring.  Additionally, this reaction under previously developed conditions 
had been shown to give only modest yields (vide supra), and presented the opportunity 
for improvement.  
     As previously stated, when catalyzed by Pd(OAc)2 and PPh3, the reaction of 
bromopyridine 88 with siloxane 104 gave a 1:1 ratio of the biaryl adduct 105 and reduced 
pyridine 98 (Table 3, entry 1).  The isolated yields of the two reaction products for this 
and subsequent entries were not measured; rather their ratios were determined by GC 
analysis.  Substitution of the more sterically hindered phosphines Pd(t-Bu)2(o-biphenyl) 
or PdCy2t-Bu for PPh3 was examined (entries 2 and 3), as these phosphines had 
previously been shown to be effective catalyst activators in recalcitrant cross-
ouplings.115, 116   Unfortunately, no changes in the product compositions were observed.  
he use of imidizolium salt 106 was also explored (entry 4), as this ligand had been 
shown to be exceptionally active in Pd-catalyzed cross-couplings.117  However, this 
alteration similarly afforded no improvement in the coupling reaction.   
 
 
c
T
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OMe
OMe
Si(OEt)3NMeO
O2N
Br
CH3
CH3
+
Conditions
NMeO
O2N CH3
CH3
OMe
OMe
NMeO
O2N
H
CH
CH
+
Entry Conditions Ratio 105 : 98a
1
TBAF, Pd(OAc)
   PPh3, DMF 1:1
2
      TBAF, Pd(OAc)2
P(t-Bu)2(o-biphenyl), DMF 1:1
3
TBAF, Pd(OAc)2
PCy2t-Bu, DMF 1:1
4
TBAF, Pd(OAc)2
N NMes Mes Cl
1,4-dioxane
1:2
5
TBAF, Pd(dba)2
   PPh3, THF only reduced
6 TBAF, Pd(PPh3)2Cl2          MeCN only reduced
7 TBAF, Pd(PPh3)4         THF 3:1
3
3
8
TMAF 3H2O, Pd(OAc)2 only reduced
roduct composition was determined by GC analysis.
88 104 105 98
106
            PPh3, DMF
 
Table 3.  Effect of catalyst system on the cross-coupling of bromopyridine 88 with 
 
ap
siloxane 104. 
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     The use of alternative Pd catalysts in the siloxane couplings was investigated also.  
Switching from Pd(OAc)2 to Pd(dba)2 (entry 5) or Pd(PPh3)2Cl2 (entry 6) gave reduced 
pyridine 98 as the sole product.  Encouraging results were, however, obtained using of 
Pd(PPh3)4 as the catalyst (entry 7).  These conditions provided a 3:1 ratio of coupled 
yridine 107 was 
btained (Scheme 21).  Lithium-halogen exchange, however, proved fruitful.  Reaction of 
9 with n-BuLi and trapping of the resultant aryllithium with Si(OEt)4 gave siloxanes 108 
and 109 in approximately a 1:1 ratio and combined 50% yield.120  Diaryl siloxane 109 is 
the result of multiple additions of the organolithium to Si(OEt)4, and its presence as a 
reaction product underscores the heightened reactivity of the organolithiums derived from 
halopyridines.  These findings are consistent with previous observations regarding 3-
bromopyridine derivatives.110  The mixture of 108 and 109 proved difficult to separate, 
product to reduced pyridine, as determined by GC, although the isolated yield of coupled 
product was only 26%.  Several other products derived from bromopyridine 88 were 
observed in the 1H NMR spectrum of the crude reaction mixture.  The use of 
tetramethylammonium fluoride as the activator118 (entry 8) gave only reduced product 98. 
     The couplings of 4-bromopyridines and appropriately functionalized D-ring siloxanes 
had thus far not provided satisfactory results.  It was thought the alternative coupling 
combination of a pyridyl siloxane and D-ring halide might offer an improvement.  This 
approach was probed using pyridyl siloxane 108, which was chosen since it possesses 
only a single (non-hydrogen) ortho substituent to silicon.  
     Treatment of bromopyridine 80 under Masuda’s previously defined hydrosilylation 
conditions119 gave none of the desired siloxane; instead only reduced p
o
7
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and inasmuch as both were expected to be capable of aryl group transfer,111 the mixture 
was taken to the next step. 
 Scheme 21 
 
     The competency of the mixture of siloxanes 108 and 109 to undergo the coupling 
reaction was first verified upon Pd-catalyzed reaction with iodobenzene, which afforded 
biaryl product 110 in excellent yield (Eq. 25).   
  
     The reaction of siloxanes 108 and 109 with streptonigrin D ring precursor 111, 
prepared as previously reported,99 gave none of the cross-coupled product; rather reduced 
NMeO
Br
CH3
CH3
[Rh(cod)Cl]2
  HSi(OEt)3
DIPEA
 DMF
NMeO CH3
CH3
1) BuLi
    Et2O
2) Si(OEt)4
NMeO
Si(OEt)3
CH3
CH3
NMeO
Si(OEt)2
CH3
CH3
2
+
ca. 50 %
1 1
80
107
108 109
NMeO
Si(OEt)3
CH3
CH3
    Ph-I, TBAF
Pd(OAc)2, PPh3
NMeO CH3
CH3
95 %
DMF
108 110
(25)
pyridine 107 was obtained (Scheme 22).  In contrast, iodobenzene 111 was found to 
as only 20%; however, the remainder of the mass balance was a mixture of 
coupled adduct 112 and reduced D ring analogue 101, indicating this reaction was 
undergo successful coupling with the less hindered PhSi(OMe)3.  The isolated yield for 
the reaction w
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effective to some extent.  The fact that pyridyl siloxane 108 and iodide 111 each 
underwent cross-coupling with unsubstituted partners, but not with each other, further 
demonstrates the sensitivity of the cross-coupling reaction to the steric environment 
possessed by both reacting partners.   
Scheme 22 
NMeO CH3
NMeO
Si(OEt)3
CH3
CH3
108
OMOM
OMe
OMe
    Et2O 
2) I2
74 %
OMOM
OMe
I
       TBAF
Pd(OAc)2, PPh3
DMF
3
Ph-Si
101 111
1) BuLi, TMEDA
OMe
           
CH
(OMe)3, TBAF
Pd(OAc) , PPh
OMOM
OMe
107
 
     The difficulty experienced in preparing the streptonigrin CD skeleton using the 
coupling method.  In particular, the use of organoboron reagents was explored.  Boronic 
metallation of arene 101, followed by reaction with B(OMe)
2 3
         DMF OMe
20 %
112
siloxane technology led us to wonder if this unit may better be synthesized using another 
acid 113 and boronic ester 115 were prepared as shown in Scheme 23.   Directed ortho-
99
the crude reaction mixture used directly in subsequent studies.  Transformation of 113 to 
3 and then aqueous acid gave 
boronic acid 113.   Due to its expected instability, this species was not isolated but rather 
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the corresponding pinacol boronic ester unexpectedly occurred with concomitant 
hydrolysis of the MOM ether, thus requiring a reprotection step to generate 115.    
pyridine 88 with a variety of arylating 
 with PhSi(OMe)3 
able 
idence of reduced pyridine 98 was observed in this reaction.   
 
Scheme 23 
OMe
OMe
OMOM
B(OH)2
pinacol, PhCH3
OH
B
O O
77 % from
      99
OMOM
B
O O1) NaH, DMF
2) MOM-Cl
98 %
OMe
OMe
OMOM
1) BuLi, TMEDA
    THF
2) B(OMe)3
3) H3O
101
113
OMe
OMe
OMe
OMe
 
     The Pd-catalyzed cross-coupling of bromo
114 115
agents was investigated (Table 4).  For reference, the coupling of 88
afforded 36% yield of the cross-coupled product and 36% of the reduced pyridine (T
4, entry 1).  Reaction of 88 with TBAT, however, gave a 67% yield of the biaryl product 
(entry 2).  No ev
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NMeO
O2N CH3
CH NMeO
O2N CH3
CH
entry Arylating Agent Co Product Yield (%)
OMe
OMOM
B
O O NMeO
O2N
H
CH3
CH3
B(OH)2
OMe
-Pd(PPh3)4, Na2CO3PhCH3, EtOH, H2O
PhCH3, EtOH, H2O
115
Br
3
Ar
3
Arylating Agent
Conditions
+
88
nditions
1 Ph-Si(OMe)3
       TBAF
Pd(OAc)2, PPh3
          DMF
NMeO
O2N CH3
CH3
36
2 TBAT Pd(OAc)2, PPh3
NMeO
O2N CH3
CH3
67
3 Ph-B(OH)2
Pd(PPh3)4, Na2CO3
PhCH3, EtOH, H2O
NMeO
O2N CH3
CH3
80
4
OMe
5
OMe
OMe
OMOM
NMeO
O2N CH3
CH3
OMe
OMOM 78
Pd(PPh3)4, Na2CO3
69
113
 Table 4.  Cross-coupling reactions of bromopyridine 88 with various arylating agents. 
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      The results in entries 1 and 2 were significant in light of the fact that cross-coupling 
reactions of aryl siloxanes such as P equire the addition of TBAF as an 
extern
s likely that 
 pathway.  
activators in the 
     The zuki conditions 
[Pd(PPh3
btained is comparable to that observed when TBAT is employed the phenylating agent.  
 at boron 
(boronic acid vs. boronic ester), or the different substitution patterns of the aromatic 
rings.  Reaction of bromopyridine 88 with boronic acid 113 resulted in the exclusive 
rmation of the cross-coupled product, which was isolated in 78% yield.  Of note is the 
fact that the crude boronic acid, obtained as described in Scheme 23, was used directly in 
the latter reaction; no further purification of this reagent was necessary. 
hSi(OMe)3 r
al activator, whereas couplings of TBAT do not.  Since TBAF is available 
commercially as a 1 M solution in THF and contains ca. 5% water, it seem
the water in the TBAF provides the hydrogen atom necessary for the reduction
Notably, other anhydrous fluoride sources such as CsF and KF have proven ineffective as 
coupling process.111 
coupling of bromopyridine 88 with PhB(OH)2 under typical Su
)4, Na2CO3, PhCH3, EtOH, H2O] afforded an 80% yield of the biaryl product 
(entry 3).  Again, no evidence of reduced pyridine 98 was observed, and the yield 
o
The use of more substituted organoboranes was examined:  reaction of 88 with pinacol 
borate 115 gave reduced pyridine as the sole reaction product; no cross-coupled adduct 
was detected (entry 4).  This was surprising given that the unsubstituted boronic acid had 
undergone coupling with 88 in high yield.  We wished to explore whether the 
discrepancy in the two reactions was the result of varying functionalities
fo
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     Two issues remained to be addressed prior to the union of the CD and AB ring 
 
 
 
systems.  First, the C-6 methyl group of the pyridine ring of 69 required oxidation to its 
acid; second, the C-2 methoxy of the pyridine ring needed to be converted to a halogen 
(or triflate), thus setting the stage for the second cross-coupling.  This latter
transformation was examined initially.      
     The original strategy was to convert the C-2 methoxy group of pyridine 69 into a 
bromide in a single chemical operation (Scheme 24).  However, reaction of 69 with PBr3
in refluxing CH2Cl2 gave only an 18% yield of the desired bromide 116, with the 
remainder of the mass balance attributed to pyridone 117.  Longer reaction times and 
larger excesses of PBr3 afforded no improvement in yield.  Similarly, change of solvent 
or substitution of the more reactive POBr3 as the brominating agent proved unsuccessful
in preparation of bromopyridine 116. 
Scheme 24      
N
O2N
MeO CH3
CH3
OMe
OMe
OMOM
Tf2O, DMAP
    CH2Cl2PBr3, CH2Cl2
90 %
H
N
O2N
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CH3
OH
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CH3
OMe
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     Pyridone 117, however, proved valuable inasmuch as this compound could readily be 
 are poor coupling partners for use in the siloxane-
 
converted to triflate 118.  In the event, careful monitoring of the reaction of 69 with PBr3 
allowed for the isolation of pyridone 117 in 90% yield.  This compound underwent facile 
reaction with Tf2O under standard conditions to deliver pyridyl triflate 118.  Due to its 
expected sensitivity, triflate 118 was not purified, although analysis of the reaction by 
TLC indicated the conversion to be quantitative. 
     The Pd-catalyzed cross-coupling of triflate 118 was investigated next.  Previous 
studies had demonstrated that triflates
based strategy, since this functional group undergoes rapid hydrolysis under the basic 
reaction conditions.  Seganish and DeShong,121 have shown, however, that aryl 
biscatechol silicates are capable of undergoing Pd-catalyzed group transfer to aryl 
triflates, with a minimal amount of accompanying triflate hydrolysis.  Treatment of 
triflate 118 with silicate 119,121 under previously defined conditions, unfortunately gave 
pyridone 117 as the sole reaction product (Scheme 25).  The high electrophilicity 
possessed by the sulfur atom of triflate 118, imposed by the alkoxy pyridine ligand, 
presumably renders this triflate more susceptible to hydrolysis than those previously 
examined. Triflate 118 did, however, undergo Stille coupling with PhSnMe3 to provide 
triaryl 120 in 56% yield from pyridone 117.  This finding demonstrated, in principle, the 
viability of our synthetic strategy. 
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Scheme 25  
     Since the cross-coupling strategy to join the AB and CD ring systems appeared
feasible, oxidation of the pyridine C-6 methyl group of 69 to its carboxylic acid (the 
functional group present at this position in streptonigrin) was explored.  This
transformation would represent the last major hurdle to be overcome prior to formation of 
the tetracyclic core, and our intention was to convert 69 to its N-oxide, followed by 
application of the pyridine N-oxide rearrangement.103  This strategy has been executed
during the course of numerous natural products syntheses, including streptonigrin,94 and 
an overview is presented in Scheme 26. 
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OMe
OH
PhSnMe , Pd(PPh )
  LiCl, 1,4-dioxane
N
O2N
CH3
CH3
OH
118
117
OMe
OH
O O
3
THF
H
NO CH3
OMe
3 3 4
56 % from pyridone 117
OMe
OMe
119
120
Si
O O
HNEt
 54
Scheme 26 
 
     The conversion of 2-methylpyridine (121) to its N-ox
N CH [O] N CH
O
Ac2O N
O
N CH
O
CH3
O
N CH
O
CH3
O
O
CH3
121 122 123 124 125
3 3 3 2-H
ide 122, followed by treatment 
122
   A series of nitro analogues of 69 were prepared and examined for their abilities to 
ndergo the oxidation (Scheme 27).  Reduction of nitropyridine 69 with H2 and Pd/C 
provided aminopyridine 127 in 57% yield (95% based upon recovered starting material).  
Attempted oxidation of 127 with m-CPBA led only to decomposition products, which 
with Ac2O, is known to give acetate 125.  The latter reaction is thought to proceed via 
initial O-acylation of 122 to give pyridium ion 123.  Loss of a proton to form 124, 
followed by acetate transfer from oxygen to carbon restores aromaticity and yields 
acetate 125.  The acetate transfer may be intra- or intermolecular.     
     Conversion of pyridine 69 to its N-oxide 126 was investigated (Eq. 26).  Attempted 
oxidation with m-CPBA and H2O2/HOAc proved ineffective, as the starting pyridine was 
recovered unchanged from the reaction mixture.  It was believed that the electron-
withdrawing effect of the nitro group of 69 was limiting the nucleophilicity of the 
pyridine.   
N
O2N
MeO CH
CH3
OMe
(26)
3
OMOM
O
m-CPBA or H2O2
3
OMe
OMOM
69
N
O2N
MeO CH
CH3
OMe
OMe
126
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was not surprising given the known reactivity of the free amino group towards 
oxidants.123, 124
acetam -CPBA or 
H2O2 position of 
128 125 
 
     It was unclear whether the lack of reactivity of pyridines 69 and 128 to oxidation was 
the result of the electron-withdrawing nature of the pyridine C-3 substituent (whether it 
be nitro or acetamido), or another unconsidered structural feature.  To address this, the 
oxidation was attempted with pyridine 80, which possesses a hydrogen substituent at C-3 
(Scheme 28).  Treatment of 80 with m-CPBA gave a mixture of N-oxide 130 and 
  Protection of the amino group of 127 proceeded uneventfully to afford 
ide 128, which similarly proved unreactive at room temperature to m
.  If more forcing conditions were applied using these reagents decom
 was observed.  Other oxidants surveyed for use with pyridine 128 included oxone
and trifluoroperoxyacetic acid;94 in both cases the starting pyridine was recovered 
unchanged.  
Scheme 27 
N
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MeO CH3
CH3
OMe
OMe
OMOM
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MeO CH3
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OMOM
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unreacted starting material, which wer  a 1:1 ratio.  This reaction will not go 
      
2 2
80 led reproducibly to N-oxide 130.  Analysis of the crude reaction mixture 
by 1 lated, 
two steps (S
e obtained in
to completion.  Larger excesses of m-CPBA, higher temperatures, or longer reaction 
times led to no improvement in the ratio of 130 to 80.  
Scheme 28 
NMeO
CH3
CH3
PBA, 2 2
H2O2, HOAc
Br
CH
O
NMeO CH3
80
Ratio 130/80 = 1:1
+      SM
Br
m-C  CH Cl NMeO
3
CH3
O
130
complete conversion by NMR
Br
CH3
130
     Gratifyingly, when performed with 1.5 Eq. of H O  and HOAc as the solvent, the 
oxidation of 
H NMR indicated complete conversion to the N-oxide.  This species was not iso
but was treated immediately with Ac2O to give rearranged product 131 in 93% yield over 
cheme 29). 
Scheme 29 
NMeO
3
CH3 Ac O
93 % from 80
NMeO
3
HNO , H SO
BrBr
CH
O
2
Br
CH
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3 2 4
NMeO
CH3
CHO
130 131 132
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     With acetate 131 in hand the sequence of transformations that would deliver the fully 
functionalized CD biaryl required for our synthesis could be explored.  One possible 
route would first incorporate the nitrogen functionality at the C-3 position of 131, and 
then commence with coupling studies and manipulations involving the acetate.  Much to 
our surprise, however, treatment of 131 under previously developed nitrating conditions 
gave aldehyde 132 as the major product.  This species presumably results from hydrolysis 
of the acetate functional group, followed by nitric acid-promoted oxidation of the 
resulting primary alcohol.126  Given the electron-withdrawing nature of the aldehyde 
substituent of 132, it is understandable why this compound is reluctant to undergo 
repared 
from me ajor 
product.  Attem at an 
nitration. 
electrophilic nitration at C-3.  Similarly, attempted nitration of alcohol 133, p
thanolysis of acetate 131 (Scheme 30), produced aldehyde 132 as the m
pted nitration of N-oxide 130 also proved fruitless.  It was clear th
acid-stable protecting group for the 1° alcohol of 133 would be required to effect 
Scheme 30 
NMeO
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MeI, Ag2O
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CH3
86 %
THF
Br Br
133
134 135
NMeO
Br
CH3
CH3
80
1) H2O2, HOAc
2) Ac2O
3) K2CO3, MeOH
68 %
NMeO
CH3
OMe
HNO3, H2SO4
51 %
NMeO
CH3
OMe
O2N
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     Several derivatives of alcohol 133, possessing various protecting groups for the 
hydroxyl functionality, were prepared and their relative abilities to undergo the nitration 
examined.  The best results were obtained using methyl ether 134, synthesized upon 
reaction of alcohol 133 with MeI and Ag O.  Notably, installation of the methyl ether 
from 133 employing NaH as the base gave less satisfactory results.  Nitration of 134 
unclear
pyridine 
     The 113 was 
exam
135
ling of bromopyridine 88, gave reduced pyridine 98 as the major reaction product 
 
 
 
 
2
under previously defined conditions gave nitropyridine 135 in modest 51% yield.  It is 
 why the yield of this nitration reaction is not as high as that observed with 
80.  Nevertheless, with 135 in hand, the stage was set to explore coupling 
reactions to prepare the CD biaryl. 
Pd-catalyzed reaction of bromopyridine 135 and crude boronic acid 
ined under a variety of conditions (Table 5).  Regretfully, the Suzuki coupling of 
 and boronic acid 113, using the same conditions that had proven successful for the 
coup
(Table 5, entry 1, yield not determined).  This was surprising since bromopyridines 88 
and 135 present the steric similarity of possessing identical substituents ortho to bromine, 
and the pyridyl rings are electronically almost identical. 
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NMeO
Br
CH3O2N
+
OMe
OMe
OMOM Conditions
Entry Conditions Major Product, yield (%)
Pd(PPh3)4, Na2CO3
3 2
NMeO
H
CH3
OMe
O2N
Pd(PPh3)4, Na2CO3
3 NR
OMe
Pd(PPh3)4, Na2CO3
           DME
Product
135 113
98
OMe B(OH)2
1 PhCH , EtOH, H O
2            DMF NR
Pd(PPh3)4, CsF
        DME
NMeO
CH3O2N
OMOM
OMe
OMe
87 %4
136
 
 
Table 5
 
 
     Although 
was assum rnishing 
the hyd  was 
investigated.
.  Cross-coupling reactions of bromopyridine 135 with boronic acid 113 
the source of the hydrogen atom on this reduction pathway is unknown, it 
ed that either the ethanol or water (co-solvents in the reaction) was fu
rogen.  Accordingly, the use anhydrous conditions for the reaction
  Substitution of DMF or DME as reaction solvent (entries 2 and 3, 
respectively), gave no evidence of reduced pyridine 98 as a reaction product; however, 
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the starting aryl bromide was recovered unchanged following the reaction.  A survey of 
the literature revealed that boronic acids could be effectively activated by CsF using 
DME as the solvent.127  In the event, coupling of bromopyridine 135 and boronic acid 
113 using Pd(PPh3)4 as the catalyst and CsF as the activator gave an 87% yield of biaryl 
136 (entry 4), without any trace of contamination by reduced pyridine 98.   
     Conversion of the methylene methoxy group of 136 to its carboxylic acid became the 
next subgoal.  This strategy would require cleavage of the methyl ether, followed by 
oxidation of the resulting primary alcohol.  Deprotection of 136 with BCl3 gave only a 
13% yield of the desired product 137 (Scheme 31).  Analysis of the crude 1H NMR 
roblem of selective deprotection 
(vide supra), this approach would allow for maximum convergence. 
spectrum indicated that several other reaction products, in which one or more of the D 
ring methyl ethers had underwent cleavage, were present in the reaction mixture; these 
species were not isolated.  The use of alternative Lewis acids to promote the deprotection 
was not examined, nor was systematic optimization of the reaction conditions 
undertaken.  Rather, the synthetic strategy was revised such that the key coupling 
reaction to prepare the CD biaryl of streptonigrin would occur between bromoester 139 
and boronic acid 113.  In addition to circumventing the p
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Scheme 31 
     Methyl ester 139 was thus prepared as shown in Scheme 32.  Deprotection of the 
thyl group of 135 with BCl3 proceeded in quantitative yield to afford alcohol 
Subsequent oxidation with KMnO4, followed by acid-catalyzed esterification, gave ester 
 in 62% yield over two steps. 
Scheme 32 
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me 138.  
139
 
   The cross-coupling of bromopyridine 139 with crude boronic acid 113, using CsF as 
lthough analysis by crude 1H NMR indicated that no products derived from the starting 
NMeO
O2N
Br
CH3
OMe
BCl3, CH2Cl2
quant.
NMeO
O2N
Br
CH3
OH 1) KMnO4, H2O
2) MeOH, H2SO4
62 %
NMeO
O2N
Br
CH3
CO2Me
135 138 139
  
the activator and Pd(PPh3)4 as catalyst, gave a 38% yield of coupled adduct 140 (Eq. 27), 
a
bromopyridine 139 other than 140 were present.  The low isolated yield of 140 is 
attributed to tedious purification (column chromatography and recrystallization), required 
to remove impurities originating from crude boronic acid 113, present in the coupling 
mixture.  Purification of the crude boronic acid mixture prior to the coupling was 
expected to simplify isolation and improve the yield of coupled product 140. 
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     The crude boronic acid mixture containing 113 could be recrystallized, which 
delivered the boronic acid completely free of impurities.  However, rapid decomposition 
of this species was observed.  It was found more convenient and equally effective to 
purify the crude boronic acid through a series of extractions,128 which delivered 113 
almost entirely free from contamination.  Following this protocol and subsequent 
 gave pyridone 141, 
which was subsequently converted to triflate 142. 
 
 
coupling with bromopyridine 139, the biaryl product 140 could be purified through 
routine column chromatography and obtained 68% yield, a marked improvement to that 
observed above.   
Biaryl 140 was elaborated into a suitable coupling partner using our previously 
established protocol (Scheme 33).  Thus, treatment of 140 with PBr3
NMeO
O2N CH3
CO2Me
139
OMe
OMe
B(OH)2
Pd(PPh3)4, CsF
        DME
68 %
O N CH
OMOM
OMe
OMe
140
(27)
Br
OMOM
113 NMeO
2 3
CO2Me
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Scheme 33 
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Synthesis of a Streptonigrin AB Coupling Precursor 
 
     Biaryl 142 represents the fully functionalized CD ring system of streptonigrin, with 
the triflate functional group at the pyridine C-2 position enabling an investigation into the 
second coupling event.  In anticipation of this, attention was focused on the preparation 
of a suitable AB ring coupling precursor.  Our initial premise was that quinoline siloxane 
143 would fulfill this role (Scheme 34, Path A), as the coupling of 143 and triflate 142 
represents the most convergent route to streptonigrin’s skeleton.  However, given the 
 
     One 
coupling of
possess a , 
thod for the 
 
 
difficulties experienced in the coupling reaction to prepare the CD biaryl, other strategies
were conceived also.      
alternative approach to the natural product framework would deploy a Heck 
 quinolinone 144 and pyridyl triflate 142.  This route is also highly 
convergent, but not without risk, since Heck couplings of α,β-unsaturated carbonyls that 
β-amino substituent (as found in 144) are as of yet unreported.  Nevertheless
the successful implementation of this strategy would constitute a novel me
preparation of 2-arylquinolines and may pave the way for the syntheses of other natural 
product targets possessing quinoline rings. 
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Scheme 34 
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     Yet a third pathway would capitalize on the Pd-catalyzed coupling of an aryl siloxane 
ith an allylic benzoate (Path C, see Scheme 5).  The required components for this 
143, quinolinone 144, or siloxane 145.  Streptonigrin A-ring 
w
process would be siloxane 145 and allylic benzoate 146, itself the product of a Pd-
catalyzed coupling of pyridyl triflate 142 and an appropriately functionalized three-
carbon fragment.  Subsequent cyclization would then deliver the tetracyclic core of 
streptonigrin.  If successful, this arylation-cyclization approach would also represent a 
novel route to the 2-arylquinoline motif.  
     Whichever of these strategies was ultimately adopted, the immediate goal became the 
design and implementation of the synthesis an AB ring precursor that could be elaborated 
into quinoline siloxane 
analogue 147 was selected for this purpose (Scheme 35), since the C-6 position of 147 
may be readily functionalized, either by directed ortho-metallation or Friedel-Crafts 
reaction of 147 (or one of its precursors).  In this way, coupling precursors 143, 144, and 
145 may each originate from 147.  
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Scheme 35 
 
 
 
 
 
 
    Thus, synthetic studies towards the preparation of 147 were begun (Scheme 36), and 
the initial surmise was that this compound would be available from resorcinol.  Indeed, 
the preparation of dinitro arene 148 from resorcinol, upon treatment with a mixture of 
nitric and sulfuric acids, had been described.129  In our hands, however, trinitroresorcinol 
149 was obtained as the sole product of this reaction (Scheme 36).  Analysis of the crude
reaction mixture by 1H NMR showed no evidence of dinitroresorcinol 148. 
 
NHBOC
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N
MeO
BOCHN
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 68
Scheme 36 
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     We were, however, able to reproduce the results of Kametani and Ogasawara  
regarding the preparation of dinitrosoresorcinol 150 (Scheme 37).  Thus, reaction of 
resorcinol with NaNO
130
ly, the order in which the latter two reactions are 
performed is critical:  attempted methylation of dinitroso species 150 resulted in 
decomposition of the starting material. 
Scheme 37  
     While not part of the initial strategy, the selective reduction of one of the nitro groups 
of 152 was examined (Scheme 38).  This would allow for the orthogonal protection of the 
two nitrogen atoms of 152, and ensure that if necessary the nitrogen functionalities could 
2, under strictly defined conditions, afforded dinitroso arene 150 in 
nearly quantitative yield.  Subsequent oxidation to the dinitro species 151 proceeded 
smoothly, and methylation of the two hydroxyl groups of 151 with dimethyl sulfate gave 
dimethoxy arene 152.  Interesting
OH
HO    NaNO2
HOAc, H2O
99 %
OH
HO
ON NO
H2O2, TFA
88 %
OH
HO
O2N NO2
K2CO3, acetone
71 %
OMe
MeO
O2N NO2
Me2SO4
150 151 152
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be independently manipulated to affec rmation.  The use of formic acid and 
diam
fruitle
 
 strategy for 
streptonigrin requires late stage oxidation of A ring precursor 155 to its p-quinone 
(Scheme 39).  This oxidation is expected to occur selectively to give streptonigrin (20), 
aving the methoxy group at C-6 of the A ring (streptonigrin numbering) unchanged.133  
xidation to give the o-quinone would be undesirable.  The ability to differentiate the 
two methoxy groups of 155 (or a precursor thereof) allows for protecting group strategies 
to be employed if necessary to ensure regioselective formation of the p-quinone.  
t quinoline fo
Pd/C has previously been shown to be selective for the monoreduction of aromatic 
ino derivatives.131  However, the reaction of 152 under these conditions proved 
ss as only starting material was recovered (Scheme 38).   
Scheme 38 
OMe
MeO
O2N NO2
HCO2H, Pd/C
      MeOH
NaHS, MeOH
No Reaction
OMe
HO
O2N NO2
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OH
MeO
O2N NO271 %
152
153 154
     Treatment of 152 with NaSH and MeOH,132 resulted in complete consumption of the 
starting material, as determined by TLC.  Following reaction work-up, analysis of the 
crude reaction mixture by 1H NMR indicated the presence of a single species of which 
one of the methoxy groups was removed (either phenol 153 or 154).  Which of the two 
regioisomers had been obtained was not established, and although neither compound was 
of immediate synthetic use, this reaction is noteworthy.  Our synthetic
le
O
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Scheme 39 
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6
      In the ef , the reduction of 152 fort to selectively reduce one of the nitro groups of 154
with H2 and Pd/C was investigated (Scheme 40).  It was observed that one of the nitro 
groups of 152 is reduced at a faster rate than the other one.  Indeed, this product (155a or 
155b) was isolated in excellent yield from the reaction mixture without any 
contamination of the other regioisomeric nitroamine.  No attempt was made at this point 
to determine which regioisomeric nitroamine was obtained.  Rather, further exposure of 
the reaction mixture to H2 and Pd/C gave diamine 156. 
Scheme 40 
OMe
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O2N NO2
H2, Pd/C
THF OMe
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OMe
MeO
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OMe
MeO
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100 %
152 155a 155b 156
NO2 O2N
OR
     After protection of diamine 156 as its bis-pivanilide (Scheme 41), the bromination of 
arene 157 was investigated.  It was hoped that this reaction would be selective for the C-6 
position, and treatment of arene 157 under standard bromination conditions delivered a 
single monobrominated species in 97% yield.  The structure of this species was 
tentatively assigned to be 158, and later confirmed by nOe analysis (vide infra). 
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Scheme 41 
 
     The ides) of arene 
57 were responsible for the regiochemical outcome of bromination, and it was 
hypothesized that bromination of diamine 156 would give the alternate regioisomer 159 
(Scheme 42).  Attempted bromination of diamine 156 under a variety of reaction 
conditions employing Br2 as the electrophile gave only decomposition.  The use of 
PyHBr•Br2 also proved unsuccessful, but reaction of 156 with HBr and DMSO  gave 
the desired product.  Ultimately this reaction was optimized to give diamine 159 in 37% 
yield.  Protection of diamine 159 as its bis-pivalanilide gave 160 in good yield.  The TLC 
and H NMR properties of the two bromobis-pivalanilides 158 and 160 were clearly 
different, and their tentative structural assignments were confirmed through selective nOe 
experiments:  the aromatic proton of 160 showed an nOe with one of the methoxy 
groups, whereas the aromatic proton of 158 did not.  At this point the synthetic route to 
AB precursor 159 had been secured, and what remained was elaboration of this 
compound to a suitable coupling partner for CD triflate 142.   
OMe
MeO
H2N NH2
2 3
THF OMe
Br2, HOAc
OMe
MeO
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37 % OMe
MeO
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1
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1
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     One proposed approach to streptonigrin involves coupling of pyridyl triflate 142 with 
quinoline siloxane 143.  The feasibility of this was explored through the attempted 
preparation of model siloxane 161 (Scheme 42).  Attempted conversion of 2-
bromoquinoline136 to quinoline siloxane 161, under previously developed hydrosilylation 
ge, 
   
      The preparation of the related quinoline stannane was investigated (Eq. 28).  
Metallation of 2-bromoquinoline, followed by reaction with ClSnMe  gave quinoline as 
the sole product.   
 
     Reversing the nucleophilic and electrophilic components in this process was however 
conditions, failed to give any siloxane product.137  Likewise, lithium halogen exchan
followed by quenching with Si(OEt)4 did not afford any of the desired siloxane.138
Scheme 42 
3
greeted with some success (Scheme 43).139  Conversion of ClSnMe3 to its sodium salt, 
followed by reaction with 2-bromoquiniline, afforded quinoline stannane 162 in 65% 
yield.   
N Br
1) RLi
2) ClSnMe3
N
(28)
N Br 31) RLi
4
N Si(OEt)
HSi(OEt)3, Pd(0)
2) Si(OEt) 161
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Scheme 43 
 
quinoline siloxane or quinoline stann  34, Path A) to prepare the ABCD 
stem of streptonigrin was not feasible.   
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     The Stille coupling of stannane 162 and triflate 118 was found to be problematic, as 
the major product of the reaction was pyridone 117.  This finding is consistent with 
previous observations in which fluorosulfonate esters derived from 2-pyridones are 
especially prone to hydrolysis (see Scheme 25).  The ability of stannane 162 to undergo 
Pd-catalyzed cross-coupling was confirmed, however, upon successful reaction with aryl 
triflate 163.121  The conclusion drawn from these results was that the coupling of a 
ane (Scheme
sy
     A second approach to the streptonigrin framework would involve the cross-coupling 
of siloxane 145 and allylic benzoate 146, followed by ring closure to form the AB 
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quinoline (Scheme 34, Path C).  The viability of this strategy was explored using the 
model system shown in Scheme 44. 
Scheme 44 
     Siloxane 164, prepared as previously described by Seganish,43 underwent Pd-
catalyzed coupling with allylic benzoate 16546 in 45% yield.  A
NHPiv
Si(OEt)3
OBz
TBAF, Pd(dba)2
THF
45 %
NHPiv
conditions
N
164 166 167
cyclization165
lthough the yield obtained 
s, the 
starting amido olefin was recovered u he use of stoichiometric amounts of 
PdCl2(PhCN)2, PdCl2, and PdBr2, which had previously been shown to affect 
intramolecular amination140 also proved unsuccessful.  Only in the reaction employing 
PdBr2 was any quinoline product obtained, and the yield in this process did not exceed 
10%.  Again, dition of bases.  
     There are two mido olefin 166: 
either the alkene is unreactive to the electrophile, or the nucleophilicity of the nitrogen 
for this reaction was lower than expected, the reaction was unoptimized and it was 
assumed that a systematic catalyst and solvent study would allow for an improvement.  
The ring closure to form the desired quinoline framework was investigated using a 
variety of electrophiles that have previously shown affinity for the alkene functionality.  
The reaction of amido olefin 166 with I2 or Hg(OAc)2, when conducted both with and 
without the addition of base, failed to provide any cyclized product.  In all instance
nchanged.  T
 these reactions were evaluated both with and without the ad
possible explanations for the lack of reactivity of a
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has been too severely diminished by the protecting group to undergo cyclization.  To 
166 was allowed to react with Br2 under standard alkene brom
e 45), resulting in the formation of dibromide 168
onstrated that the alkene functionality of 166
question this, olefin inating 
conditions (Schem  in 48% yield.  This 
result clearly dem  was sufficiently 
 closure.  Attempts to remove the pivalanilide protecting group of 
168 at room temperature under acidic conditions were unsuccessful, as only unreacted 
starting material was recovered.  If elevated temperatures were used, decomposition 
roducts were observed. 
 
     Thus a similar reaction sequence using the more labile BOC group as a protection 
strategy for the nitrogen atom (Scheme 46) was performed.  The cross-coupling of N-
BOC protected aryl siloxane 16943 with allylic benzoate 165 gave adduct 170 in 55% 
yield.  Removal of BOC group proceeded uneventfully upon treatment with 3M HCl to 
give aniline 171.  Reaction of 171 with I2 and NaHCO3 failed to induce cyclization, as the 
starting amine was recovered unchanged.  Attempted ring closure using Pd reagents gave 
a complex mixture of inseparable products and this pathway was not pursued further.  
nucleophilic, and the failures observed in the cyclization reaction were due to a lack of 
nucleophilicity of the protected nitrogen.  Interestingly, treatment of dibromide 168 with 
base failed to affect ring
p
Scheme 45 
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Scheme 46 
e coupling process is highly sensitive to the 
Streptonigrin C ring precursor 139, prepared in 10 steps from ethyl 2-methylacetoacetate, 
NHBOC
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     The conclusion drawn from these studies was that the cross-coupling of a protected (o-
amino)-arylsiloxane with an allylic benzoate serves as a useful tactic in linking the major 
subunits of streptonigrin.  However, further investigations into the annulation reaction of 
171 are warranted if this strategy is to be adopted for the preparation of the natural 
product. 
     In summary, a series of 4-bromopyridines have been synthesized and their abilities to 
undergo Pd-catalyzed coupling with streptonigrin D ring siloxane analogues evaluated.  
This method proved generally amenable to the preparation of sterically demanding 
biaryls.  However, it was shown that th
electronic properties of both coupling partners. 
     The current status of the total synthesis is summarized in Schemes 47 and 48.  
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was shown to undergo Suzuki coupling with boronic acid 133 (prepared in three steps 
from 2,3-dimethoxybenzaldehyde) in good yield.  This reaction was found to be highly 
dependent on the conditions employed d solvent).  Triflate 142, representing 
 
 
 
 (activator an
the fully functionalized CD ring system, has thus been prepared in a highly convergent
manner in 13 steps at the longest linear sequence.  
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     Streptonigrin AB ring analogue 159 pared in 6 steps from resorcinol.  The 
results of model studies indicate that, following transformation to siloxane 145, the 
) represents a 
viable strate  49).  Further 
studies ar , which will be 
required for com
 has been pre
coupling of this piece with allylic benzoate 146 (derived from triflate 142
gy for the union of the molecule’s two major subunits (Scheme
e needed to evaluate the viability of the ring closure of 172
pletion of the synthesis.    
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Experimental 
 
General Methods.  H and C NMR spectra were recorded on a Bruker DRX-400 
spectrometer.  Chemical shifts are reported in parts per million (ppm).  Coupling 
constants (J) are given in Hertz (Hz).  Spin multiplicities are indicated by standard 
otation. 
     Infrared spectra were recorded on a Nicolet 560 FT-IR spectrophotometer.  Band 
positions are given in reciprocal centimeters (cm-1) and relative intensities are listed as br 
road), s (strong), m (medium), or w (weak). 
   Melting points were taken in Kimax soft capillary tubes using a Thomas-Hoover Uni-
Melt capillary melting point apparatus equipped with a calibrated thermometer. 
   Low resolution (LRMS) and high resolution (HRMS) were obtained on a JEOL SX-
02A instrument. 
     Thin layer chromatography (TLC) was performed on 0.25 mm Analtech silica-coated 
glass plates, with compounds being identified in one or both of the following manners: 
V (254 nm) and vanillin/sulfuric acid/ethanol charring.  Flash chromatography was 
erformed using glass columns and “medium pressure” silica gel (Sorbent Technologies, 
45-70 μ). 
     Tetrahydrofuran (THF), diethyl ether, toluene, and 1,4-dioxane were distilled from 
sodium/benzophenone ketyl.  N,N-Dimethylformamide (DMF) was distilled from 
calcium hydride and dried over 4Å molecular sieves.  Pyridine, methylene chloride, and 
1,2-dichloroethane (DCE) were distilled from calcium hydride.  N,N,N,N-
tetramethylethylenediamine (TMEDA) and 1,2-dimethoxyethane (DME) were distilled 
1 13
n
(b
  
  
1
U
p
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from sodium metal.  PBr3, oxalyl chloride, and B(OMe)3 were distilled prior to use.  
Triphenylphosphine was recrystallized from hexanes.  All other reagents were purchased 
and used as received.  Glassware used in the reactions was dried overnight in an oven at 
120 °C.  All reactions were performed under an atmosphere of argon unless otherwise 
noted. 
 
Amino ester 74  
EtO CH3
CH3
O NH2
 
This reaction was not performed under inert atmosphere.  Ethyl 2-methylacetoacetate 
(100 g, 0.693 mol) was absorbed onto 135 g of bentonite K-10 clay.  To the mixture was 
added 85 mL (1.3 mol) of 14.9 M ammonium hydroxide and this mixture stirred at room 
temperature for 24 h.  The clay was washed 4x with 500 mL of CH2Cl2 and the combined 
washings dried over MgSO4 and concentrated in vacuo to yield 90.9 g (92%) of amino 
ester 74 as a white, crystalline solid, mp 46-49 °C (literature104 mp 52 °C), which was 
used without further purification.  The 1H NMR spectrum matched that of the reported 
compound.104 IR (CCl4) 3506 (m), 3309 (m), 2975 (m), 2905 (m), 2866 (w), 1666 (s), 
1616 (s) cm-1.  1H NMR (CDCl3) δ 1.24 (t, J = 7 Hz, 3H), 1.72 (s, 3H), 1.91 (s, 3H), 4.10 
(q, J = 7 Hz, 2H).  13C NMR (CDCl3) δ 12.8, 15.0, 21.6, 59.3, 89.4, 156.6, 171.2.  EI-MS 
m/z 143 (100), 114 (26), 98 (93), 69 (62), 42 (23).  HRMS for C7H13NO2 calcd 143.0946, 
found 143.0951.  
 
Pyridone 72a   
H
NO
OH
CH3H3C
CH3
 
odium ethoxide was generated by adding 3.65 g (0.158 mol) of sodium metal to 55 mL 
of ethanol.  To this solution was added a solution of 27.2 mL (0.158 mol) of diethyl 
methylmalonate in 8 mL of toluene.  The resulting solution was stirred at room 
temperature for 1 h.  A solution of 22.6 g (0.158 mol) of amino ester 74 in 22 mL of 
S
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toluene was added over a period of 20 min.  The reaction was heated at reflux for 24 h, 
during which time a white precipitate formed.  After cooling, the mixture was diluted 
with water and stirred for 30 min.  The phases were separated and the aqueous layer 
washed with toluene.  The aqueous layer was acidified with conc HCl to pH 7.0, and the 
precipitate thus obtained filtered and dried to yield 16.8 g (69%) of pyridone 72a as a 
white, crystalline solid, mp 270-275 °C (decomp, literature104 mp 260 °C), which was 
1
compound.104  IR (KBr) 3429 (br), 3262 (br), 2955 (m), 2928 (m), 1631 (s) cm-1.  1H 
13
53.0790, 
used without further purification.  The H NMR spectrum matched that of the reported 
NMR (DMSO-d6) δ 1.80 (s, 3H), 1.83 (s, 3H), 2.06 (s, 3H), 9.12 (br s, 1H), 10.85 (br s, 
1H).  C NMR (DMSO-d6) δ 6.9, 8.2, 14.0, 101.5, 101.8, 135.8, 160.0, 161.3.  EI-MS 
m/z 153 (100), 124 (32), 98 (41), 78 (37), 63 (33).  HRMS for C8H10NO2 calcd 1
found 153.0783.   
 
Pyridone 72b  
H
NO
OH
CH3EtO2C
CH3
 
Sodium ethoxide was generated by adding 23.0 g (1.00 mol) of sodium metal to 400 mL 
of ethanol.  To this solution was added a solution of 145 mL (0.959 mol) of diethyl 
malonate in 55 mL of toluene.  The resulting yellow solution was stirred at room 
temperature for 1 h.  A solution of 68.9 g (0.481 mol) of amino ester 74 in 150 mL of 
toluene was added, and the resulting solution refluxed for 4 d during which time a white 
precipitate formed.  After cooling, the mixture was diluted with water and stirred for 30 
min.  The phases were separated and the aqueous layer washed with toluene.  The 
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aqueous layer was concentrated in vacuo to remove the ethanol and acidified with conc 
HCl.  The precipitate thus obtained was filtered, washed with water, and dried to yield 
61.78 g (61%) of pyridone 72b as a white, crystalline solid. mp 215-220 °C (decomp 
literature105 mp 216-221 °C), which was used without further purification.  The 1H NMR 
spectrum matched that of the reported compound.105  IR (CCl4) 3317 (w), 3165 (w), 2986 
), 2932 (m), 2866 (m), 2803 (m), 1654 (s) cm-1.  1H NMR (CDCl3) δ 1.42 (t, J = 8 Hz, 
3H), 1.65 (s, 3H), 1.95 (s, 3H), 4.41 (q, J = 8 Hz, 2H), 12.33 (s, 1 H).  13C NMR (CDCl3) 
δ 9.9, 14.5, 17.9, 62.1, 96.8, 106.5, 149.2, 163.0, 172.9, 175.2.  EI-MS m/z 211 (93), 165 
(100), 139 (48), 137 (47), 109 (64).  HRMS for C10H13NO4 calcd 211.0845, found 
211.0844.      
 
Pyridone 72c 
 
A solution of 61.78 g (0.2925 mol of pyridone 72b and 111 g of NaOH (2.78 mol) in 1.3 
L of water was heated at reflux for 2 h.  The solution was cooled to 0 °C, brought to pH = 
7 with conc HCl, and stirred at room temperature for 12 h.  The precipitate thus obtained 
was filtered and washed with water to yield 40.29 g (99%) of pyridone 72c as a white 
solid, mp > 320 °C.  IR (KBr) 3421 (w), 3266 (w), 3087 (m), 3002 (m), 2928 (m), 2882 
(m), 1662 (s), 1616 (s) cm-1.  1H NMR (DMSO-d6) δ 1.79 (s, 3H), 2.09 (s, 3H), 5.49 (s, 
1H), 10.53 (br s, 1H), 10.91 (br s, 1H).  13C NMR (DMSO-d6) δ 9.8, 16.7, 96.1, 104.2, 
142.3, 163.7, 167.3.  EI-MS m/z 139 (100), 111 (76), 110 (80), 69 (72), 44 (84).  HRMS 
for C7H9NO2 calcd 139.0633, found 139.0638. 
(m
H
NO
OH
CH3
CH3
 85
Triflate 75 and bis-triflate 76 
NTfO
OTf
CH3H3C
CH3HNO
OTf
CH3H3C
CH3
 
A solution of 115 mg (0.751 mmol) of hydroxypyridone 72a and a catalytic amount of 
2 4
DMAP in 10 mL pyridine was cooled to 0 °C.  To this solution was added dropwise 140 
μL (0.826 mmol) of Tf2O, causing the immediate evolution of gas.  The solution was 
stirred at 0 °C for 1 h, quenched with water, and neutralized with 1 M HCl.  The solution 
was extracted 3x with Et O and the combined organic extracts dried over MgSO  and 
concentrated in vacuo.  Purification by column chromatography (3:1 hexanes:EtOAc, Rf 
= 0.67) yielded 127 mg (41%) of bis-triflate 76 as a colorless oil.  IR (CCl4) 3006 (w), 
2959 (w), 2924 (w), 2874 (w), 2858 (w), 1615 (m) cm-1.  1H NMR (CDCl3) δ 2.24 (s, 
3H), 2.26 (s, 3H), 2.44 (s, 3H).  13C NMR (CDCl3) δ 9.6, 12.1, 21.4, 115.4, 117.4 (q, J = 
320 Hz), 117.6 (q, J = 320 Hz), 125.3, 151.6, 153.7, 155.7. 
82 mg (38%) of triflate 75, was also obtained by column chromatography (Rf = 0.39) as a 
white, crystalline solid, mp 91-93 °C.  IR (CCl4) 3596 (s), 3002 (w), 2936 (w), 2925 (w), 
2870 (w), 1623 (m).  1H NMR (CDCl3) δ 2.12 (s, 3H), 2.15 (s, 3H), 2.38 (s, 3H), 5.64 (s, 
1H).  13C NMR (CDCl3) δ 6.7, 9.0, 20.0, 105.5, 115.8, 116.4 (q, J = 320 Hz), 150.4, 
151.7, 159.5. 
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Bromopyridone 77 
H
NO
CH3H3C
CH3
A mixture of 5.0 g (0.033 mol) of pyridone 72a and 14 g (0.049 mol) of POBr  was 
Recrystallization from ethanol afforded 4.3 g (60%) of bromopyridone 77 as a white, 
104 1
104
-1 1 δ
13
Br  
3
heated at 110° C for 1 h.  The solution was allowed to cool to room temperature and 
quenched with water. The precipitate thus obtained was filtered and washed with water.  
crystalline solid, mp 226-228 °C (literature  mp 227° C).  The H NMR spectrum 
matched that of the reported compound.   IR (CCl4) 3289 (w), 3134 (w), 2979 (m), 
2928 (m), 2870 (m), 2769 (m), 1647 (s), 1616 (m) cm .  H NMR (DMSO-d6)  2.01 (s, 
3H), 2.05 (s, 3H), 2.27 (s, 3H).  C NMR (DMSO-d6) δ 17.3, 17.5, 17.7, 111.2, 125.6, 
139.1, 140.7, 161.0.  EI-MS m/z 217 (100), 215 (94) 188 (45), 186 (40).  HRMS for 
C8H10BrNO2 calcd 216.9925, found 216.9917. 
 
Bromopyridine 78      
NMeO
Br
CH3H3C
 
To a suspension of 3.45 g (0.0125 mol) of Ag
CH3
2CO3 and 3.58 g (0.0177 mol) of pyridone 
77 in 30 mL of benzene was added 1.25 mL (0.0200 mol) of MeI.  The resulting solution 
was heated in the dark at 45 °C for 12 h.  The mixture was cooled to 0 °C, filtered, and 
the filtrate washed with 50 mL of 2% NaHCO3, followed by 50 mL water.  The benzene 
was evaporated under reduced pressure and the remaining aqueous solution extracted 3x 
with CH2Cl2.  The combined organic extracts were dried over MgSO4 and concentrated in 
 87
vacuo to give 3.84 g (100%) of pyridine 78 as a white, crystalline solid, mp 44-45° C, 
which was used without further purification.  IR (CCl4) 3006 (w), 2953 (w), 2951 (m), 
2920 (w), 2893 (w), 2866 (w) cm-1.  1H NMR (CDCl3) δ 2.19 (s, 3H), 2.22 (s, 3H), 2.37 
(s, 3H), 3.83 (s, 3H).  13C NMR (CDCl3) δ 14.5, 19.1, 23.8, 53.9, 118.4, 124.0, 139.4, 
151.1, 159.9.  EI-MS m/z 231 (100), 229 (87), 216 (29).  HRMS for C9BrH12NO2 calcd 
229.0102, found 229.0104.    
 
Pyridine 80  
NMeO
Br
CH3
CH3
 
his compound was obtained directly from pyridone 72c.  A mixture of 22.06 g (0.1585 
ypyridone 72c and 30.54 g (0.1068 mol) of POBr3 in 30 mL DMF were 
°C for 45 min.  After cooling, water was added and the resulting solution 
brought to pH = 7 with Na2CO3.  The precipitate thus obtained was filtered, washed with 
ater and then Et O to yield 19.80 g of a yellow solid.  Although the intermediate 
bromopyridone could be purified, it was more convenient to use the crude material in the 
next step. 
To a solution of the crude bromopyridone and 32.2 g (0.117 mol) of Ag CO  in 110 mL 
CHCl  was added 20.0 mL (0.314 mmol) MeI and the mixture heated at 50 °C for 24 h in 
the dark.  After cooling, the mixture was filtered and the filtrate concentrated in vacuo.  
Purification by column chromatography (19:1 hexanes:EtOAc, Rf = 0.38) afforded 12.70 
g (37% from 72c) of pyridine 80 as a white, crystalline solid, mp = 38-41 °C.  IR (CCl4) 
3014 (w), 2971 (w), 2944 (w), 2897 (w) cm-1.  1H NMR (CDCl3) δ 2.27 (s, 3H), 2.44 (s, 
T
mol) of hydrox
heated at 110 
w 2
2 3
3
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3H), 3.85 (s, 3H), 6.80 (s, 1H).  13C NMR (CDCl3) δ 18.0, 24.1, 54.0, 111.6, 124.0, 
137.3, 155.4, 161.9.  EI-MS m/z 216 (98), 214 (100), 187 (37), 185 (32). 
Acid bromide 83 
 
NBr
BrO  
A mixture of 2.00 g (9.51 mmol) of pyridone 72b and 8.20 g (28.6 mmol) of POBr
CH3
CH3
Br
yield 2.05 g (58%) of acid bromide 83 as a white solid, mp 105-108 °C, which was used 
-1 1 -1 13
(70), 370 (25), 294 (29), 292 (54), 290 (27), 155 (60), 119 (100), 85 (93).  HRMS for C-
H Br NO calcd 369.8088, found 369.8095. 
 
Methyl ester 84 
3 was 
heated at 110 °C for 4 h.  The solution was allowed to cool to room temperature and 
water was added.  The precipitate thus obtained was filtered and washed with water to 
immediately without further purification.  IR (CCl4) 2959 (w), 2925 (w), 2862 (w), 1790 
(s) cm .  H NMR (CDCl3) δ 2.37 (s, 3H), 2.60 (s, 3H) cm .  C NMR (CDCl3) δ 18.7, 
24.4, 130.0, 130.6, 132.5, 138.4, 160.7, 161.1.  FAB-MS m/z 376 (19), 374 (67), 372 
8 6 3
NBr
Br
CH3MeO2C
CH3
 
Freshly prepared acid bromide 83 (1.10 g, 3.41 mmol) was dissolved in 20 mL of CH2Cl2 
and 20 mL MeOH.  To this solution was added 2.0 mL of pyridine and the resulting 
 stirred for 3 h at room temperature.  The solution was concentrated under 
reduced pressure and the residue dissolved in 20 mL of CH2Cl2 and washed with 20 mL 
solution
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of water, followed by 20 mL of brine.  The organic layer was dried over MgSO4 and 
concentrated in vacuo.  Recrystallization from MeOH afforded 720 mg (74%) of methyl 
ester 84 as a white, crystalline solid, mp 133-136 °C.  IR (CCl4) 2955 (w), 2920 (w), 
-1 1 132950 (w), 1748 (s) cm .  H NMR (CDCl3) δ 2.33 (s, 3H), 2.56 (s, 3H), 3.96 (s, 3H).  C 
NMR (CDCl3) δ 18.5, 23.8, 53.3, 131.6, 132.7, 133.2, 133.7, 159.4, 165.8.  FAB-MS m/z 
326 (42), 324 (100), 322 (53), 292 (22).  HRMS for C9H9Br2NO2 calcd 321.9078, found 
321.9081.  
 
Amino ester 85 
EtO CH3
K-10 clay.  To this mixture was added 9.2 mL (0.084 mol) of benzylamine and the 
resulting mixture stirred at room temperature for 7 h.  The clay was washed 4x with 200 
NHBn
CH3
O
 
Ethyl 2-methylacetoacetate (10.0 mL, 0.0707 mol) was absorbed onto 17 g of bentonite 
2Cl2 and the combined washings dried over MgSO4 and concentrated in vacuo to 
85 as a pale yellow oil, which was used without further 
purification.  IR (CCl4) 3250 (br), 3173 (w), 3087 (w), 3064 (w), 3025 (w), 2975 (m), 
2932 (m), 2862 (w), 1720 (w), 1647 (s) cm-1.  1H NMR (CDCl3) δ 1.26 (t, J = 7 Hz, 3H), 
3
14 19 2
mL CH
yield 11.9 g (73%) of amino ester 
1.78 (s, 3H), 1.97 (s, 3H), 4.10 (q, J = 7 Hz, 2H), 4.41 (d, J = 6 Hz, 2H), 7.25 (m, 5 H), 
9.63 (br s, 1H).  13C NMR (CDCl ) δ 12.8, 14.7, 15.3, 47.1, 58.8, 87.6, 126.7, 127.1, 
128.7, 139.5, 159.4, 171.1.  FAB-MS m/z (234 (70), 233 (100), 232 (48), 188 (40), 91 
(63).  HRMS for C H NO  calcd 233.1416, found 233.141. 
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Amide 86 
EtO CH3
O O
CH3
BnN
CH3
O OEt
 
A solution of 1.11 g (8.4 mmol) of ethyl malonic acid and 1 drop DMF in 20 mL CH2Cl2 
was cooled to 0 °C.  Oxalyl chloride was added dropwise, causing the evolution of gas.  
The resulting solution was stirred 1.5 h at 0 °C, and then allowed to warm to room 
temperature and stirred an additional 2 h.  A solution of 3.91 g (16.8 mmol) of amine 85 
in 20 mL CH2Cl2 was added and the resulting solution stirred 20 h at room temperature.  
To the solution was added 40 mL brine and the layers separated.  The aqueous layer was 
further extracted 2x with CH2Cl2 and the combined organic extracts dried over MgSO4 
and concentrated in vacuo.  Purification by column chromatography (3:1 hexanes:EtOAc, 
Rf = 0.19 afforded 900 mg (31%) of the title compound as a yellow oil.  IR (CCl4) 3091 
(w), 3068 (w), 3029 (w), 2979 (m), 2936 (m), 2874 (w), 1741 (s), 1718 (s), 1670 (s) cm .  
H NMR (CDCl3)  1.17 (t, J = 7 Hz, 3H), 1.26 (t, J = 7 Hz, 3H), 1.75 (s, 3H), 1.86 (s, 
3H), 3.37 (d, J = 15 Hz, 1H), 3.43 (d, J = 15 Hz, 1H), 3.93 (m, 2H), 4.18 (q, J = 7 Hz, 
2H), 4.37 (d, J = 14 Hz, 1H), 4.84 (d, J = 14 Hz, 1H), 7.25 (m, 5H).  C NMR (CDCl3) δ 
14.3, 14.5, 16.3, 20.2, 41.9, 51.0, 61.6, 61.7, 96.0, 128.0, 128.8, 129.5, 129.6, 137.4, 
140.9, 165.9, 167.6, 168.3.  FAB-MS m/z 348 (100), 91 (63).  HRMS for C19H25NO5 
calcd 348.1824, found, 348.1822.  
 
-1
1 δ
13
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Pyridone 87 
Bn
NO CH3
EtO2C
OH
CH3
 
as generated upon the addition of 100 mg (4.35 mmol) of sodium 
metal to 50 mL of EtOH.  A solution of 850 mg (2.35 mmol) of amido ester 86 in 50 mL 
EtOH was added and the resulting solution stirred at room temperature for 30 min.  The 
99.  
 
Sodium ethoxide w
solution was concentrated in vacuo and the residue extracted 2x with Et2O.  The 
combined organic extracts were dried over MgSO4 and concentrated in vacuo to afford 
715 mg (100%) of pyridone 87 as a white solid, which was used without further 
purification.  IR (CCl4) 3091 (w), 3068 (w), 3033 (w), 2943 (w), 2905 (w), 2866 (w), 
1666 (s), 1638 (m), 1608 (s) cm-1.  1H NMR (CDCl3) δ 1.42 (t, J = 7 Hz, 3H), 2.01 (s, 
3H), 2.24 (s, 3H), 4.43 (q, J = 7 Hz, 2H), 5.30 (br s, 2H), 7.09 (d, J = 8 Hz, 2H), 7.21 (m 
3H), 13.87 (s, 1H). 13C NMR (CDCl3) δ 11.0, 14.7, 17.9, 47.7, 62.4, 97.0, 107.0, 111.3, 
126.6, 127.6, 129.2, 137.2, 150.5, 161.0, 173.5, 173.7.  FAB-MS m/z 302 (100).  HRMS 
for C17H19NO4 calcd 302.1392, found 302.13
 
Nitropyridine 88
NMeO
Br
CH3
CH3
O2N
 
A solution of 1.32 g (6.11 mmol) of pyridine 80, 0.60 mL (8.6 mmol) of HNO  and 15 
mL of H SO  was stirred at room temperature for 14 h.  The solution was diluted with 
100 mL of water and neutralized with Na CO .  The solution was extracted 2x with 100 
mL Et O and the combined organic extracts dried over MgSO  and concentrated in vacuo 
3
2 4
2 3
2 4
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to yield 1.55 g (97%) of nitropyridine 88 as a yellow solid, mp 86-89 °C, which was used 
without further purification.  IR (CCl4) 3025 (w), 2998 (w), 2951 (w), 2924 (w), 2905 
(w), 1581 (s) cm-1.  1H NMR (CDCl3) δ 2.33 (s, 3H), 2.51 (s, 3H), 3.97 (s, 3H).  13C 
NMR (CDCl3) δ 18.5, 24.4, 55.0, 125.2, 127.5, 152.5, 156.9.  FAB-MS m/z 263 (66), 261 
(61), 155 (57), 152 (59), 119 (68), 103 (48), 85 (100).  HRMS for C8H9BrN2O3 calcd 
260.9875, found 260.9872. 
 
Aminopyridine 89 
NMeO CH3
Br
CH3H2N
 
To a solution of 1.39 g (5.32 mmol) of nitropyridine 88, 28 mL of EtOH, and 7 mL of 
f
4
1654 (m), 1612 (s) cm .  H NMR (CDCl3) δ 2.29 (s, 3H), 2.41 (s 3H), 3.98 (s, 3H), 4.05 
(br s, 2H).  C NMR (CDCl3) δ 18.2, 22.3, 53.3, 119.8, 122.7, 127.1, 140.7, 149.6.  EI-
MS m/z 232 (98), 230 (100), 189 (68), 187 (68).  HRMS for C8H11BrN2O calcd 
232.0034, found 232.0049. 
 
water was added 3.5 g (63 mmol) of Fe and 2 drops of conc HCl.  The resulting solution 
was heated at reflux for 2 h.  After cooling, the solution was filtered and the filtrate 
concentrated in vacuo.  Purification by column chromatography (9:1 hexanes:EtOAc, R  
= 0.40) gave 0.800 g (65%) of aminopyridine 89 as a yellow crystalline solid, mp 52-54 
°C.  IR (CCl ) 3487 (s), 3394 (s), 3014 (w), 2983 (w), 2948 (m), 2920 (w), 2858 (w), 
-1 1
13
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Azide 94 
NMeO
Br
CH3
CH3
N3
 
A solution of 41 mg (0.62 mmol) of NaNO  in 2 mL water was cooled to 0 °C.  To this 
solution was added dropwise a solution of 121 mg (0.524 mmol) of aminopyridine 89 in 
5 mL 10% HCl.  The resulting solution was allowed to warm to room temperature and 
stirred 15 min.  The solution was then cooled to 0 °C and a solution of 35 mg (0.55 
3
to room temperature and stirred 45 min.  The solution was basicified with Na2CO3 and 
2 2 4
concentrated in vacuo.  Purification by column chromatography (19:1 hexanes:EtOAc, Rf 
4
.  H NMR (CDCl3) δ 2.25 (s, 3H), 2.40 (s, 3H), 3.96 (s, 3H).  C (CDCl3) δ 18.7, 23.5, 
54.3, 120.8, 125.3, 127.6, 149.8, 155.0.  
 
2
mmol) NaN  in 2 mL water added dropwise.  The resulting solution was allowed to warm 
extracted 3x with CH Cl .  The combined organic extracts were dried over MgSO  and 
= 0.40) afforded 109 mg (80%) of the title compound as a yellow oil.  IR (CCl ) 3018 
(w), 2990 (w), 2948 (m), 2925 (m), 2870 (w), 2851 (w), 2175 (m), 2132 (s), 2101 (s) cm-
1 1  13  
Acetamide 95 
NMeO
CH3
CH3
AcHN
Br  
 To a suspension of 244 mg (1.06 mmol) of aminopyridine 89 and 1.05 g (7.60 mmol) of 
K2CO3 in 15 mL THF was added 0.45 mL (6.3 mmol) of AcCl.  The reaction was stirred 
for 45 min at room temperature and quenched with water.  The solution was extracted 3x 
with Et2O and the combined organic extracts dried over MgSO4 and concentrated in 
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vacuo.  Purification by column chromatography (1:1 hexanes:EtOAc, Rf = 0.19) afforded 
198 mg (69%) of the title compound as a white, crystalline solid, mp 175-176 °C.  IR 
(CCl4) 3433 (m), 3386 (w), 3014 (w), 2983 (w), 2948 (m), 2924 (m), 2854 (w), 1701 (s) 
-1 1cm .  H NMR (CDCl3) δ 2.19 (s, 3H), 2.25 (s, 3H), 2.45 (s, 3H), 3.90 (s, 3H), 6.65 (br s, 
1H).  13C NMR (CDCl3) δ 16.9, 21.7, 21.8, 52.2, 115.5, 122.7, 135.0, 151.4, 155.4, 167.1.  
FAB-MS m/z 275 (100), 273 (97), 233 (34), 231 (39).  HRMS for C10H13BrN2O2 calcd 
273.0239, found 273.0245. 
 
Carbamate 96 
NMe
Br
OMe
 
The title compound was obtained directly from nitropyridine 88.  The reduction of 940 
mg (3.60 mmol) of nitropyridine 88 was performed as described above (to give amine 
89).  The crude product thus obtained was dissolved in 40 mL THF.  To this solution was 
added 5.6 g (26 mmol) of BOC
Me NHBOC
c amount of DMAP, and the resulting 
lution heated at reflux for 5 h.  After cooling, 3.0 g (22 mmol) of K2CO3 and 40 mL 
 and the resulting solution heated at reflux for 24 h.  After cooling, 100 
mL of 0.5 M HCl was added and the solution was extracted 3x with 100 mL EtOAc.  The 
combined organic extracts were dried over MgSO4 and concentrated in vacuo.  
2O and a catalyti
so
MeOH were added
Purification by column chromatography (3:1 hexanes:EtOAc Rf = 0.43) afforded 751 mg 
(63%) of the title compound as a white crystalline solid, mp = 101-104 °C.  IR (CCl4) 
3429 (m), 3010 (w), 2979 (m), 2951 (w), 2928 (w), 1740 (s) cm-1.  1H NMR (CDCl3) δ 
1.47 (s, 9H), 2.02 (s, 3H), 2.43 (s, 3H), 3.91 (s, 3H), 5.88 (br s, 1H).  13C NMR (CDCl3) 
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δ 16.9, 21.7, 26.5, 52.1, 78.9, 116.0, 122.5, 134.8, 150.5, 151.7, 155.4.  EI-MS m/z 332 
(12), 330 (13), 232 (90), 230 (88), 57 (100).  HRMS for C13H9BrN2O3 calcd 330.0579, 
found 330.0579. 
 
General procedure for the siloxane-based synthesis of biaryls.  Coupling reactions 
were performed under identical conditions using 20 mole % Pd(OAc)2 and 40 mole % 
Ph3, 2 equiv of  siloxane and 2 equiv of TBAF.  The following example is illustrative. 
Table 1, entry 3, (biaryl 90) 
12 h. The reaction was qu r and the solution extracted 3x with Et O.  The 
combined organic extracts were dried over MgSO4 and concentrated in vacuo.  
Purification by column chromatography (hexanes, Rf = 0.14) afforded 230 mg (89%) of 
the title compound as a colorless oil.  IR (CCl4) 3084 (w), 3056 (w), 2967 (s), 2944 (s), 
2924 (m), 2858 (w) cm .  1H NMR (CDCl3) δ 1.82 (s, 3H), 1.83 (s, 3H), 2.42 (s, 3H), 
3.94 (s, 3H), 7.05 (d, J = 7 Hz, 2 H), 7.33 (d, J = 7 Hz, 1H), 7.40 (t, J = 7 Hz, 2H).  13C 
NMR (CDCl3) δ 13.5, 16.3, 23.1, 53.6, 115.6, 121.9, 127.5, 128.8, 128.9, 140.9, 120.7, 
P
 
NMeO
CH
CH3
H C 33
 
To a solution of 261 mg (1.15 mmol) of bromopyridine 78, 440 mg (2.22 mmol) of 
phenyltrimethoxysilane, 52 mg (0.21 mmol) of Pd(OAc)2, and 110 mg (0.419 mmol) of 
PPh3 in 10 mL DMF was added 2.2 mL (2.2 mmol) of a 1M solution of TBAF in THF.  
The solution was degassed via a single freeze-pump-thaw cycle and heated at 80 °C for 
enched with wate 2
-1
 96
152.0, 160.0.  EI-MS m/z 227 (70), 226 (100).  HRMS for C15H17NO calcd 226.1232, 
found 226.1228   
 
Table 1, entry 1 (biaryl 110) 
NMeO
CH3
CH3
 
Following column chromatography (19:1 hexanes:EtOAc, Rf = 0.29), the title compound 
was obtained in 97% yield as a white, crystalline solid, mp 52-54 °C,   IR (CCl4) 3087 
(w), 3060 (w), 2948 (m), 2920 (m), 2850 (m) cm-1.  1H NMR (CDCl3) δ 2.06 (s, 3H), 
2.46 (s, 3H), 3.90 (s, 3H), 6.45 (s, 1H), 7.25 (d, J = 8 Hz, 2H), 7.37 (m, 3H).  13C NMR 
(CDCl3) δ 14.4, 22.1, 52.3, 106.6, 120.2, 126.5, 127.2, 127.6, 139.2, 151.7, 135.8, 160.3.  
EI-MS m/z 213 (94), 212 (100), 184 (49), 183 (56), 128 (51), 127 (38).  HRMS for 
C14H15NO calcd 213.1154, found 213.1149.  
 
Table 1, entry 2 
NMeO CH3
CH3
H3C
 
1
Following column chromatography (19:1 hexanes:EtOAc, Rf = 0.32), the title compound 
was obtained in 10% yield as a colorless oil.  H NMR (CDCl3) δ 1.86 (s, 3H), 2.04 (s, 
3H), 2.46 (s, 3H), 3.90 (s, 3H), 6.36 (s, 1H), 7.02 (d, J = 8 Hz, 1H), 7.23 (m, 3H). 
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Table 1, entry 4 (biaryl 92)  
NMeO
CH3
CH3
H3C
H3C
 
Following column chromatography (19:1 hexanes:EtOAc, Rf = 0.23), the title compound 
was obtained in 10% yield as a pale yellow oil.  IR (CCl4) 3072 (w), 3002 (m), 2921 (m), 
1581 (m) cm .  H NMR (C-1 1 DCl3) δ 1.70 (s, 3H), 1.71 (s, 3H), 1.87 (s, 3H), 2.36 (s, 3H), 
.89 (s, 3H), 6.84 (d, J = 7 Hz, 1H), 7.24 (m, 3H); 13C (CDCl3) δ 13.1, 15.8, 19.8, 23.0, 
.9, 126.4, 127.9, 128.6, 130.4, 135.6, 139.6, 150.8, 151.5, 160.1.  EI-MS 
m/z 241 (100), 240 (84), 226 (94), 216 (65).  
 
3
53.5, 115.5, 121
Table 1, entry 5  
NMeO
CH3
CH3
O
O
 
Following column chromatography (19:1 hexanes:EtOAc, R
H3C
f = 0.30), the title compound 
was obtained in 61% yield as a colorless oil.  IR (CCl4) 3072 (w), 3002 (m), 2948 (s), 
2920 (s), 2829 (s), 1581 (m) cm-1.  1H NMR (CDCl3) δ 1.79 (s, 3H), 1.81 (s, 3H), 2.35 (s, 
3H), 3.87 (s, 3H), 5.93 (s, 2H), 6.43 (d, J = 7 Hz, 1H), 6.44 (s, 1H), 6.79 (d, J = 7 Hz, 
1H)  13C NMR (CDCl3) δ 13.5, 16.4, 23.1, 53.6, 101.5, 108.8, 109.5, 116.0, 122.1, 122.2, 
133.7, 147.0, 148.1, 150.1, 151.6, 160.0.  EI-MS m/z 271 (74), 270 (100).  HRMS for 
C16H17NO3 calcd 270.1130, found 270.1125. 
 
 98
 99
Biaryl 97 and pyridine 98 
 
NMeO
CH3
CH
O2N
3
NMeO
CH3
CH3
O2N
 
f  
ite, crystalline solid, mp 79-82 °C.  IR (CCl4) 3087 (w), 
3064 (w), 3025 (w), 2990 (w), 2955 (w), 2920 (w), 2901 (w), 2874 (w) cm-1.  1H NMR 
 1.95 (s, 3H), 2.50 (s, 3H), 4.00 (s, 3H), 7.16 (m, 2 H), 7.40 (m, 3H).  13C NMR 
 16.0, 23.8, 54.6, 123.2, 128.6, 129.1, 129.3, 133.9, 134.4, 144.3, 152.1, 157.1.  
I-MS m/z 250 (100), 211 (57).  HRMS for C H N O  calcd 258.1004, found 258.0997.   
Reduced pyridine 98 was obtained in 36% yield as a white, crystalline solid, mp 69-72 
°C, R  = 0.15 (hexanes).  IR (CCl ) 3025 (m), 2994 (m), 2955 (m), 2928 (m), 2866 (m) 
-1 1 13
Via Siloxane Coupling (Table 1) 
These compounds were prepared according to the general siloxane coupling procedure 
outlined previously.  Following column chromatography (hexanes, R  = 0.19), biaryl 97
isolated in 36% yield as a wh
(CDCl3) δ
(CDCl3) δ
E 14 14 2 3
f 4
cm .  H NMR (CDCl3) δ 2.25 (s, 3H), 2.45 (s, 3H), 4.05 (s, 3H), 8.03 (s, 1H).  C NMR 
(CDCl3) δ 18.2, 23.1, 54.9, 124.8, 131.5, 136.4, 154.4, 161.8.  
 
Via Suzuki Coupling (Table 4) 
A solution of 278 mg (1.06 mmol) of 4-bromopyridine 88, 202 mg (1.66 mmol) 
phenylboronic acid, 270 mg (2.55 mmol) Na2CO3, and 206 mg (0.178 mmol) Pd(PPh3)4, 
2 mL EtOH, 2 mL water, and 25 mL toluene was heated at reflux for 12 h.  After cooling, 
30 mL of water was added and the solution extracted 3x with Et2O.  The combined 
organic extracts were dried over MgSO4 and concentrated in vacuo.  Purification by 
column chromatography afforded 220 mg (80%) of the title biaryl. 
 
Phenol 100 
OH
OMe
OMe  
To a mixture of 9.3 mL (0.066 mol) of 30% H2O2 and 9.3 g of boric acid (0.15 mol) in 90 
ectral data matched that of the reported 
ompound.113  IR (CCl4) 3530 (m), 3002 (m), 2979 (m), 2936 (m), 2893 (m), 2866 (m), 
R (CDCl3) δ 3.84 (s, 3H), 3.88 (s, 3H), 6.74 (br s, 1 H), 6.45 (dd, 
J = 8 Hz, 1 Hz, 1H), 6.58 (dd, J = 8 Hz, 1 Hz, 1H), 6.90 (t, J = 8 Hz, 1H).  13C NMR 
(CDCl3) δ 56.3, 61.4, 104.5, 108.5, 124.5, 136.0, 149.9, 153.0.    
 
mL of THF was added 3 mL of sulfuric acid.  The mixture was stirred at room 
temperature for 30 min and a solution of 5.0 g (0.030 mol) of 2,3-dimethoxybenaldehyde 
in 30 mL of THF was added.  The mixture was heated at 50° C for 24 h, quenched with 
saturated NaHCO3, and filtered.  The filtrate was extracted 3x with Et2O and the 
combined organic extracts dried over MgSO4 and concentrated in vacuo.  Purification by 
column chromatography (3:1 hexanes:EtOAc Rf = 0.29)  afforded 3.22 g (70%) of the 
title compound as a pale yellow oil.  Sp
c
2835 (m) cm-1.  1H NM
 100
MOM ether 101 
OMOM
OMe
OMe  
NaH (60% dispersion in mineral oil, 1.2 g, 30 mmol) was washed 2x with 3 mL of 
 organic extracts dried over MgSO4 and 
oncentrated in vacuo to afford 4.40 g (100%) of the title compound as a pale yellow oil, 
ithout further purification.  IR (CCl4) 2998 (m), 2955 (s), 2932 (s), 
2834 (m), 1596 (s) cm-1.  1H NMR (CDCl3) δ 3.47 (s, 3H), 3.82 (s, 3H), 3.83 (s, 3H), 
5.18 (s, 2H), 6.58 (d, J = 8 Hz, 1H), 6.74 (d, J = 8 Hz, 1H), 6.92 (t, J = 8 Hz, 1H).  13C 
NMR (CDCl3)  56.4, 56.6, 61.3, 95.7, 106.7, 109.9, 124.1, 139.6, 151.4, 154.1. 
hexanes.  To the solid was added 20 mL of DMF and the resulting suspension cooled to 
0° C.  A solution of 3.42 g (22.2 mmol) of phenol 100 in 15 mL of DMF was added and 
the resulting solution stirred at 0° C for 30 min.  To the solution was added 2.3 mL (30 
mmol) of MOM-Cl, causing the immediate evolution of gas.  The solution was allowed to 
warm to room temperature and quenched with 50 mL of water.  The solution was 
extracted 3x with ether and the combined
c
which was used w
 δ
 
Siloxane 102 
OMOM
OMe
Si(OEt)3
A solution of 1.88 g (9.49 mmol) of arene 101 and 2.2 mL (1.4 mmol) of TMEDA in 40 
mL of THF was cooled to -78 °C.  To this solution was added dropwise BuLi (15.3 mL 
of a 0.80 M solution, 0.014 mol) and the res
OMe  
ulting solution stirred at -78 °C for 10 min 
nd then allowed to warm to 0 °C and stirred an additional 2 h.  This solution was added a
 101
over 30 min to 4.3 mL (1.9 mmol) of Si(OEt)4 dissolved in 40 mL of THF at –78 °C.  
The resulting solution was allowed to warm to room temperature, quenched with water, 
and extracted 3x with Et2O.  The combined organic extracts were dried over MgSO4 and 
concentrated in vacuo.  Purification by column chromatography (15% EtOAc:hexanes, Rf 
= 0.24) afforded 850 mg (25%) of siloxane 102 as a pale yellow oil.  IR (CCl4) 2971 (s), 
-1 1
13
 
Siloxane 104 
s and 15 mL of THF was 
eated to reflux and a solution of 3.49 g (16.1 mmol) of 4-bromoveritrole114 in 10 mL 
in.  The mixture was refluxed an additional 1.5 h and the 
concentrated in vacuo.  Purification by column chromatography (9:1 hexanes:EtOAc, Rf 
2924 (s), 2889 (s), 2835 (m) cm .  H NMR (CDCl3) δ 1.22 (t, J = 7 Hz, 9 H), 3.62 (s, 
3H), 3.81 (s, 3 H), 3.85 (s, 3 H), 3.86 (q, J = 7 Hz, 6H), 5.17 (s, 2 H), 6.67 (d, J = 8 Hz, 1 
H), 7.32 (d, J = 8 Hz, 1 H).  C NMR CDCl3 δ 18.6, 56.3, 57.9, 59.0, 61.1, 99.6, 108.0, 
117.2, 123.6, 141.9, 155.5, 156.6.  EI-MS m/z 360 (87), 271 (95), 270 (100), 255 (53), 
166 (56), 45 (53).  HRMS for C15H28O7Si calcd 360.1590, found 360.1604.  
Si(OEt)
 
Mg turnings were washed 3x with 1M HCl, 3x with water, once with EtOH, and finally 
with Et2O.  A mixture of 430 mg (17.7 mmol) of the turning
3
OMe
OMe
h
THF added dropwise over 30 m
solution transferred via cannula to a solution of 10.0 mL (44.6 mmol) of Si(OEt)4 in 50 
mL THF.  The resulting solution was stirred at room tmeperature for 20 h and 
concentrated in vacuo.  The residue was dissolved in 150 mL pentane and washed 2x 
with water and once with brine.  The organic phase was dried over MgSO4 and 
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= 0.15) afforded 1.50 g (31%) of the title compound as a colorless oil.  IR (CCl4) 3064 
(w), 3014 (w), 2951 (m), 2920 (m), 2858 (w), 1612 (s), 1604 (s) cm-1.  1H NMR (CDCl3) 
 1.23 (t, J = 7 Hz, 9H), 3.84 (q, J = 7 Hz, 6H), 3.87 (s, 3H), 3.88 (s, 3H), 6.89 (d, J = 8 
3 (s, 1H), 7.23 (d, J = 8Hz, 1H).  13C NMR δ 18.7, 56.1, 56.2, 59.1, 111.3, 
117.2, 122.6, 128.8, 149.0, 151.3.  FAB-MS m/z 300 (100), 255 (52).  HRMS for 
C14H19O5
δ
Hz, 1H), 7.1
Si calcd 300.1393, found 300.1385.                                      
 
Biaryl 105 
NMeO
O2N CH3
CH3
OMe
4 3
3
OMe  
This compound was prepared according to the general siloxane coupling procedure 
outlined above.  Purification by column chromatography (3:1 hexanes:EtOAc, Rf = 0.31) 
afforded the title compound in 21% yield as a yellow, crystalline solid, mp 129-132 °C.  
IR (CCl ) 3006 (m), 2959 (m), 2932 (m), 2913 (m), 2839 (m) cm-1.  1H NMR (CDCl ) δ 
1.99 (s, 3H), 2.49 (s, 3H), 3.82 (s, 3H), 3.88 (s, 3H), 3.99 (s, 3H), 6.66 (s, 1H), 6.72 (d, J 
= 8 Hz, 1H), 6.88 (d, J = 8 Hz, 1H).  13C NMR (CDCl ) δ 14.5, 22.2, 53.0, 54.7, 54.8, 
109.9, 110.3, 119.7, 121.8, 124.5, 133.5, 142.5, 147.7, 148.2, 150.5, 155.4.  FAB-MS m/z 
319 (H+, 100) 318 (41).  HRMS for C16H18N2O5 calcd 318.1216, found 318.1209. 
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Siloxanes 108 and 109 
NMeO
Si(OEt)3
CH3
CH3
NMeO
Si(OEt)2
CH3
CH3
2
+
 
11 
A solution of 583 mg (2.70 mmol) of pyridyl bromide 80 in 100 mL Et2O was cooled to –
78 °C.  To the solution was added dropwise 3.5 mL (3.0 mmol) of a 0.85 M solution of 
BuLi in hexanes, and the resulting solution stirred at this temperature for 75 min.  A 
solution of 1.2 mL (5.4 mmol) Si(OEt)4 in 100 mL Et2O was added dropwise at this 
temperature and the solution stirred a further 1 h at –78 °C.  The solution was warmed to 
room temperature, quenched with water, and the phases separated.  The aqueous layer 
was extracted with Et2O and the combined organic extracts dried over MgSO4 and 
concentrated in vacuo.  Purification by column chromatography (19:1 hexanes:EtOAc, Rf 
= 0.40) gave 475 mg (ca. 50%) of a 1:1 ratio of siloxanes 108 and 109, as determined by 
1H NMR.  1H NMR (CDCl3) δ 1.22 (t, J = 7 Hz, 15 H), 2.05 (s, 3H), 2.30 (s, 3H), 2.35 (s, 
3H), 2.39 (s, 3H), 3.73 (q, J = 7 Hz, 2H), 3.82 (q, J = 7 Hz, 6H), 3.87 (s, 3H), 3.89 (s, 
3H), 6.92 (s, 1H), 7.04 (s, 1H).   
 
Iodobenzene 1
OMOM
OMe
OMe
I
 
This compound was prepared according to the procedure of Holzapfel.99  A solution of 
1.01 g (5.10 mmol) of arene 101 and 0.85 mL (5.6 mmol) TMEDA in 75 mL Et2O was 
cooled to –78 °C.  To the solution was added dropwise 7.0 mL (5.6 mmol) of a 0.80 M 
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solution of BuLi in hexanes.  The resultant solution was allowed to warm to room 
temperature and stirred 30 min.  The solution was cooled to –78 °C and a solution of 2.64 
g (10.4 mmol) I2 in 25 mL Et2O was added dropwise over 20 min.  The resulting solution 
was warmed to room temperature and quenched upon the addition of aqueous Na2S2O3.  
The phases were separated and the aqueous layer extracted with Et2O.  The combined 
organic extracts were dried over MgSO4 and concentrated in vacuo to a pale yellow oil, 
which used without further purification.  The 1H NMR spectra matched that of the 
reported compound.99  1H NMR (CDCl3) 3.65 (s, 3H), 3.81 (s, 3H), 3.83 (s, 3H), 5.18 (s, 
2H), 6.48 (d, J = 9 Hz, 1H), 7.42 (d, J = 9 Hz, 1H). 
 
Biaryl 112 
OMe
OMe
OMOM
 
This compound was prepared from iodide 107 and PhSi(OMe) , according to the general 
method outlined above for couplings of siloxanes.  Following column column 
chromatography (15% EtOAc:hexanes, R  = 0.29) biaryl 112 was isolated in 20% yield as 
a colorless oil.  IR (CCl ) 3056 (w), 2994 (m), 2959 (m), 2932 (m), 2901 (m), 2831 (m), 
1681 (w), 1608 (m) cm-1.  1H NMR (CDCl ) δ 3.05 (s, 3 H), 3.84 (s, 3 H), 3.91 (s, 3H), 
4.87 (s, 2 H), 6.75 (d, J = 7 Hz, 1 H), 7.02 (d, J = 7 Hz, 1 H), 7.28 (t, J = 7 Hz, 1 H), 7.36 
13 δ
3
f
4
3
(t, J = 7 Hz, 2 H), 7.49 (d, J = 7 Hz, 2H).  C NMR (CDCl3)  56.5, 57.3, 61.3, 99.5, 
108.3, 125.3, 127.1, 128.5, 129.9, 130.0, 138.9, 142.8, 148.5, 153.5.  FAB-MS m/z 274 
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(76), 243 (100), 242 (47), 45 (47).  The remainder of the mass balance was an inseperable 
mixture of the desired product and a small amount of reduced iodide 101.      
 
Boronic Ester 114 
OH
B
OMe
OMe
OO
 
This compound was prepared directly from crude boronic acid 113.  A solution of 0.477 
mg (1.97 mmol) of the crude boronic acid (obtained as described below for the 
preparation of biaryl 69) and 361 mg (3.05 mmol) pinacol in 20 mL toluene was heated at 
reflux and water azeotropically removed.  After 5 h the reaction was concentrated and the 
residue purified by column chromatography (3:1 hexanes:EtOAc, Rf = 0.23) to yield 390 
mg (77%) of the title compound as a white, crystalline solid, mp 109-111 °C.  IR (CCl4) 
3441 (br), 3002 (m), 2979 (m), 2932 (m), 2835 (m), 1623 (s) cm-1.  1H NMR (CDCl3) δ 
1.33 (s, 12 H), 3.85 (s, 3H), 3.85 (s, 3H), 6.48 (d, 1 H, J = 8 Hz), 7.30 (d, 1 H, J = 8 Hz), 
7.74 (s, 1H).  13C NMR (CDCl3) δ 25.2, 56.4, 61.0, 84.7, 104.5, 131.4, 136.4, 157.2, 
157.5.  FAB-MS m/z 281 (74), 280 (100), 223 (48).  HRMS for C14H21BO5 calcd 
280.1482, found 280.1488.  
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Boronic Ester 115 
OMe
OMe
 
To 10 mg (0.25 mmol) of a 60% dispersion of NaH in mineral oil suspended in 5 mL 
DMF was added 48 mg (0.17 mmol) of phenol 114.  The mixture was stirred 15 min and 
0.050 mL (0.66 mmol) MOM-Cl was added.  The resulting solution was stirred at room 
temperature for 1 h and quenched with water.  The solution was extracted 3x with Et
OMOM
B
O O
2O 
and the combined organic extracts dried over MgSO4 and concentrated in vacuo to give 
55 mg (98%) of the title compound as colorless oil, which was used without further 
purification.  1H NMR (CDCl3) δ 1.31 (s, 12H), 3.60 (s, 3H), 3.82 (s, 3H), 3.88 (s, 3H), 
5.13 (s, 2H), 6.68 (d, J = 8 Hz, 1H), 7.45 (d, J = 8 Hz, 1H).     
 
Biaryl 69 
NMeO CH3
O2N CH3
OMe
OMOM
 
A solution of 1.08 g (5.45 mmol) MOM-protected phenol 101 and 0.90 mL (5.4 mmol) 
TMEDA in 30 mL THF was cooled to –78 °C.  To the solution was added dropwise 7.0 
OMe
mL (5.6 mmol) of a 0.8 M solution of n-BuLi in hexanes and the resulting solution 
allowed to warm to 0 °C.  After 1.5 h at 0 °C the solution was cooled to –78 °C and 1.2 
mL (11 mmol) of B(OMe)3 in 30 mL THF was added over 10 min.  The resulting 
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solution was allowed over 1 h to warm to room temperature and stirred an additional 16 
h.  30 mL of 5% HCl was added and the solution extracted 3x with Et2O.  The combined 
organic extracts were dried over MgSO4 and concentrated in vacuo to yield crude boronic 
acid 113 a white, crystalline solid, which was used immediately in the next step without 
further purification. 
     A mixture of the crude boronic acid, 645 mg (2.47 mmol) 4-bromopyridine 88, 615 
mg (5.32 mmol) Pd(PPh3)4, and 579 mg (5.46 mmol) Na2CO3, 60 mL toluene, 6 mL H2O, 
and 6 mL EtOH was heated at reflux for 40 h.  After cooling, 60 mL of water was added 
and the solution extracted 3x with Et2O.  The combined organic extracts were dried over 
gSO4 and concentrated in vacuo.  Purification by column chromatography (3:1 
Ac, Rf = 0.25) afforded a yellow solid, which was recrystallized from 
hexanes/Et2O to yield 737 mg (78%) of the title compound as a white, crystalline solid, 
mp 128-129 °C.  IR (CCl4) 2990 (m), 2955 (m), 2924 (m), 2874 (m), 2831 (m) cm-1.  1H 
NMR (CDCl3) δ 1.97 (s, 3H), 2.49 (s, 3H), 3.11 (s, 3H), 3.85 (s, 3H), 3.86 (s, 3H), 3.99 
M
hexanes:EtO
(s, 3H), 4.80 (d, J = 6 Hz, 1 H), 5.08 (d, J = 6 Hz, 1H), 6.69 (d, J = 8 Hz, 1H), 6.76 (d, J 
= 8 Hz, 1 H).  13C NMR (CDCl3) δ 15.9, 23.7, 54.5, 56.4, 57.1, 61.4, 99.4, 108.3, 121.1, 
124.2, 124.9, 134.8, 141.4, 142.8, 148.5, 152.2, 155.0, 156.5.  EI-MS m/z 378 (100), 332 
(37).  HRMS for C18H22N2O7 calcd 378.1427, found  378.1443. 
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2-Bromopyridine 108 
NBr CH3
O2N CH3
OMe
OH
 
To a solution of 101 mg (0.267 mmol) of 2-methoxypyridine 69 in 3 mL CH2Cl2 was 
added 0.50 mL (5.3 mmol) of PBr3.  The resulting solution was heated at 90 °C for 20 h.  
After cooling, the solution was diluted with water, neutralized with NaHCO3, and 
OMe
extracted 3x with Et2O.  The combined organic extracts were dried over MgSO4 and 
concentrated in vacuo.  Purification by column chromatography (1:1 hexanes:EtOAc, Rf 
= 0.45) gave 20 mg (18%) of the title compound as a white, crystalline solid, mp 139-144 
°C.  IR (CCl4) 3526 (br), 3010 (w), 2959 (m), 2928 (m), 2854 (w) cm-1.  1H NMR 
(CDCl3) δ 2.03 (s, 3H), 2.59 (s, 3H), 3.87 (s, 3H), 3.92 (s, 3H), 5.96 (s, 1H), 6.50 (d, J = 
9 Hz, 1H), 6.70 (d, J = 9 Hz, 1H).  13C NMR (CDCl3) δ 16.4, 23.7, 56.3, 61.6, 104.8, 
112.4, 124.2, 127.8, 133.1, 135.9, 140.5, 147.1, 153.7, 160.1.  FAB-MS m/z 385 (100), 
383 (98), 309 (87).  HRMS for C15H15BrN2O5 calcd 385.0222, found 385.0218. 
 
Pyridone 117 
H
NO CH3
O2N CH3
OMe
OMe
OH
 
To a solution of 324 mg (0.856 mmol) of 2-methoxypyridine 69 in 25 mL CH2Cl2 was 
added 0.40 mL (4.2 mmol) PBr3 and the resulting solution heated at reflux for 2.5 h.  
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After cooling water was added and the mixture neutralized with Na2CO3.  The phases 
were separated and the aqueous layer extracted 2x with CH2Cl2.  The combined organic 
extracts were concentrated in vacuo and the residue triturated with EtOAc to give 247 mg 
(90%) of the title compound as a white crystalline solid, mp > 330 °C.  IR (KBr) 3313 
-1 1(br), 3002 (m), 2936 (m), 2878 (m), 2831 (m), 1662 (s) cm .  H NMR (DMSO – d6) δ 
1.65 (s, 3H), 2.24 (s, 3H), 3.65 (s, 3H), 3.76 (s, 3H), 6.52 (d, J = 10 Hz, 1H), 6.59 (d, J = 
10 Hz, 1H), 9.23 (s, 1H), 12.52 (br s, 1H).  EI-MS m/z 320 (100).  HRMS for C15H15N2O6 
calcd 320.1008, found 320.1003. 
 
Triaryl 120 
NH3C
H3C NO2
OMe
OMe
OH
 
This compound was prepared directly from pyridone 117.  A suspension of 42 mg (0.13 
mmol) of pyridone 117 and 19 mg (0.16 mmol) DMAP in 1 mL CH2Cl2 was cooled to 0 
°C.  Tf2O (0.050 mL, 0.30 mmol) was added dropwise and the resulting solution stirred at 
0 °C for 12 h.  The reaction was quenched with water and extracted 3x with CH2Cl2.  The 
4combined organic extracts were dried over MgSO  and concentrated in vacuo.  The 
residue was dissolved in 7 mL of 1,4-dioxane and 29 mg (0.68 mmol) of LiCl and 0.025 
mL (0.14 mmol) of PhSnMe3 were added.  The resulting solution was stirred for room 
temperature for 30 min and 13 mg (0.011 mmol) Pd(PPh3)4 was added and the solution 
heated at reflux for 18 h.  After cooling, 10% ammonium chloride was added and the 
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solution extracted 3x with CH2Cl2.  The combined organic extracts were dried over 
MgSO4 and concentrated in vacuo.  Purification by column chromatography (3:1 
hexanes:EtOAc, Rf = 0.14) and subsequent recrystallization from hexanes/Et2O afforded 
28 mg (56%) of the title compound as a white, crystalline solid, mp 165-168 °C.  IR 
(CCl4) 3518 (m), 3068 (w), 3010 (w), 2959 (m), 2924 (s), 2850 (m), 2835 (m), 1623 (s) 
cm-1.  1H NMR (CDCl3) δ 2.11 (s, 3H), 2.66 (s, 3H), 3.88 (s, 3H), 3.93 (s, 3H), 5.97 (s, 
1H), 6.51 (d, J = 9 Hz, 1H), 6.74 (d, J = 9 Hz, 1H), 7.39 (m, 3H), 7.58 (m, 2H).  FAB-MS 
m/z 381 (100).  HRMS for C21H20N2O5 calcd 381.1450, found 381.1450.    
 
Aminopyridine 127 
N
H2N
MeO CH3
CH3
OMe
OMOM
OMe  
H2 was bubbled through a suspension of 937 mg (2.48 mmol) of nitropyridine 69 and 680 
mg 10% Pd/C in 100 mL THF for 3 d.  The mixture was filtered through a pad of celite 
and the filtrate concentrated in vacuo.  Purification by column chromatography (3:1 
hexanes:EtOAc, Rf = 0.10) gave 494 mg (57%) of the title compound as a white, 
crystalline solid, mp 97-100 °C.  IR (CCl4) 3487 (w), 3386 (w), 2998 (m), 2948 (s), 2928 
(s), 2854 (m), 2835 (m), 1608 (s) cm-1.  1H NMR (C6D6) δ 1.96 (s, 3H), 2.44 (s, 3H), 2.88 
(s, 3H), 3.27 (s, 3H), 3.41 (br s, 2H), 3.71 (s, 3H), 3.89 (s, 3H), 4.86 (s, 2H), 6.32 (d, J = 
9 Hz, 1H), 6.66 (d, J = 9 Hz, 1H).  13C NMR (C6D6) δ 16.2, 22.4, 53.2, 55.7, 56.4, 60.7, 
99.3, 109.2, 123.4, 124.8, 127.7, 131.9, 140.7, 144.0, 149.5, 150.8, 154.3, 204.0  EI-MS 
m/z 348 (100), 315 (33), 299 (42).  HRMS for C18H24N2O5 calcd 348.1685, found 
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348.1688.  An additional 356 mg (38%) of unreacted starting material (Rf = 0.25) was 
collected as well.    
 
Acetamide 128 
N
AcHN
MeO CH3
CH3
OMe
OMOM
 
To a solution of 134 mg (0.385 mmol) of aminopyridine 127 in 7 mL THF was added 
0.150 mL (1.59 mmol) of Ac
OMe
 (d, J = 8 
z, 1H).  13C NMR (CD3OD) δ 15.1, 21.3, 21.9, 52.9, 55.6, 55.7, 60.3, 99.1, 108.3, 
24.1, 124.8, 142.5, 147.7, 148.3, 152.9, 154.2, 157.7, 171.7.  EI-MS m/z 
390 (74), 299 (100).  HRMS for C20H26N2O6 calcd 390.1791, found 390.1790.  
 
2O and the resulting solution heated at 70 °C for 16 h.  After 
cooling, the solution was diluted with water and extracted 3x with Et2O.  The combined 
organic extracts were dried over MgSO4 and concentrated in vacuo to yield 140 mg 
(94%) of the title compound, which was used without further purification.  IR (CCl4) 
3394 (br), 3006 (m), 2948 (m), 2928 (m), 2835 (m), 1693 (s) cm-1.  1H NMR (CD3OD) δ 
1.83 (s, 3H), 1.94 (s, 3H), 2.43 (s, 3H), 2.92 (s, 3H), 3.81 (s, 3H), 3.86 (s, 3H), 3.89 (s, 
3H), 4.78 (d, J = 6 Hz, 1H), 4.87 (d, J = 6 Hz, 1H), 6.76 (d, J = 8 Hz, 1H), 6.84
H
116.8, 123.7, 1
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Acetate 131 
NMeO
Br
CH3
OAc
 
2
This compound was prepared directly from pyridine 80.  A solution of 520 mg (2.41 
mmol) pyridine 80 and 1.0 mL (7.2 mmol) of 30% H2O2 in 15 mL HOAc were heated at 
60 °C for 3 d.  After cooling, the solution was concentrated in vacuo and the residue 
dissolved in 10 mL Ac O.  This solution was heated at 120 °C for 24 h and concentrated 
in vacuo to give 628 mg (93%) of the title compound as a pale brown oil, which was used 
without further purification.  IR (CCl4) 3017 (m), 2983 (m), 2948 (m), 2924 (m), 2905 
(m), 2854 (m), 1748 (s) cm-1.  1H NMR (CDCl3) δ 2.11 (s, 3H), 2.28 (s, 3H), 3.85 (s, 3H), 
5.14 (s, 2H), 6.93 (s, 1H).  13C NMR (CDCl3) δ 16.9, 21.2, 54.0, 66.3, 114.4, 124.9, 
138.1, 151.1, 162.2, 171.1. 
 
Aldehyde 132 
NMeO
Br
CHO
 
A solution of 322 mg (1.17 mmol) acetate 131, 0.50 mL HNO
CH3
3, and 2.5 mL H2SO4 was 
heated at 50 °C for 48 h.  After cooling, the solution was diluted with water, neutralized 
with NaHCO3, and extracted 3x with EtOAc.  The combined organic extracts were dried 
over MgSO4 and concentrated in vacuo to yield 173 mg (64%) of the title compound as a 
white, crystalline solid, mp 65-69 °C.  IR (CCl4) 2959 (m), 2920 (m), 2862 (m), 2819 
(m), 1717 (s) cm-1.  1H NMR (CDCl3) δ 2.62 (s, 3H), 3.96 (s, 3H), 7.16 (s, 1H), 9.97 (s, 
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1H).  13C NMR (CDCl3) δ 16.3, 54.3, 199.0, 129.1, 139.9, 147.3, 162.5, 194.5.    
 
Alcohol 133 
NMeO
Br
CH3
OH
 
This compound was obtained directly from pyridine 80.  A solution of 701 mg (3.24 
mmol) of pyridine 80, 0.50 mL (4.4 mmol) 30% H2O2, and 22 mL acetic acid was heated 
at 60 °C for 3 d.  After cooling, the solution was concentrated in vacuo and the residue 
dissolved in 7 mL of acetic anhydride.  This solution was heated at 120 °C for 2 h.  After 
cooling, the solution was concentrated in vacuo.  To the residue was added 2.28 g (16.5 
mmol) K2CO3 and 25 mL methanol.  The resulting solution was stirred at room 
temperature for 18 h and concentrated in vacuo.  The residue was suspended in water and 
extracted 3x with Et2O.  The combined organic extracts were dried over MgSO4 and 
3
3
concentrated in vacuo to yield 509 mg (68%) of the title compound as a white, crystalline 
solid, mp 49-52 °C, which was used without further purification.  IR (CCl4) 3456 (br), 
3021 (m), 2983 (m), 2951 (m), 2928 (m), 2866 (m) cm-1.  1H NMR (CDCl ) δ 2.15 (s, 
3H), 3.82 (br s, 1H), 3.92 (s, 3H), 4.62 (s, 2H), 6.90 (s, 1H).  13C NMR (CDCl ) δ 15.3, 
54.2, 62.3, 112.7, 122.0, 138.2, 154.4, 161.9. 
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Methyl ether 134 
NMeO
Br
CH3
OMe
 
To a solution of 2.16 g (9.31 mmol) of alcohol 133 and 3.31 g (14.3 mmol) of Ag2O in 40 
mL THF was added 2.0 mL (32 mmol) of iodomethane.  The resulting solution was 
heated in the dark at 65 °C for 4 d.  The suspension was filtered through a pad of celite 
and the filtrate concentrated in vacuo to yield 1.97 g (86%) of the title compound as a 
3
white, crystalline solid, mp = 48-50 °C, which was used without further purification.  IR 
(CCl4) 3014 (w), 2986 (w), 2951 (m), 2928 (m), 2893 (w), 2918 (w) cm-1.  1H NMR 
(CDCl3) δ 2.34 (s, 3H), 3.39 (s, 3H), 3.88 (s, 3H), 4.50 (s, 2H), 6.93 (s, 1H).  13C NMR 
(CDCl ) δ 17.0, 54.1, 58.9, 75.6, 114.0, 125.9, 138.3, 153.6, 162.0. 
 
Nitropyridine 135 
NMeO
Br
OMe
 
A solution of 914 mg (3.71 mmol) of pyridine 134 in 1.5 mL of HNO
CH3O2N
ith water, 
eutralized with Na2CO3, and extracted 3x with Et2O.  The combined organic extracts 
were dried over MgSO4 and concentrated in vacuo.  Purification by column 
chromatography (9:1 hexanes:EtOAc, Rf = 0.11) afforded 550 mg (51%) of the title 
compound as a white, crystalline solid, mp 47-50 °C.  IR (CCl4) 3025 (m), 2990 (m), 
2959 (m), 2928 (m), 2921 (m), 2819 (m) cm-1.  1H NMR (CDCl3) δ 2.40 (s, 3H), 3.40 (s, 
3 and 8.5 mL of 
H2SO4 was stirred at room temperature for 2 d.  The solution was diluted w
n
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3H), 4.00 (s, 3H), 4.53 (s, 2H).  13C NMR (CDCl3) δ 17.5, 55.1, 59.1, 75.1, 111.3, 127.2, 
128.7, 152.9, 154.8.  EI-MS m/z 292 (6), 290 (8), 262 (91), 260 (100), 247 (30), 245 (28).  
HRMS for C9H11BrN2O4 calcd 291.9882, found 291.9893. 
 
Biaryl 136  
NMeO
32
OMOM
OMe
OMe
 
Boronic acid 113 was prepared as described above.  A solution of 287 mg (1.19 mmol) of 
the crude boronic acid, 190 mg (0.653 mmol) of bromopyridine 135, 350 mg (2.30 mmol) 
CsF, and 138 mg (0.119 mmol) Pd(PPh
CH
OMe
O N
was diluted with water and the solution extracted 3x with 
t2O.  The combined organic extracts were dried over MgSO4 and concentrated in vacuo.  
column chromatography (3:1 hexanes:EtOAc, Rf = 0.09) yielded 233 mg 
(87%) of the title compound as a white, crystalline solid, mp 71-73 °C.  IR (CCl4) 2994 
(m), 2963 (m), 2932 (m), 2893 (m), 2835 (m), 1600 (m) cm-1.  1H NMR (CDCl3) δ 2.07 
Alcohol 137 
3)4 in 6 mL DME was heated at reflux for 20 h.  
After cooling, the solution 
E
Purification by 
(s, 3H), 3.09 (s, 3H), 3.43 (s, 3H), 3.84 (s, 3H), 3.86 (s, 3H), 4.02 (s, 3H), 4.52 (d, J = 12 
Hz, 1H), 4.56 (d, J = 12 Hz, 1H), 4.80 (d, J = 6 Hz, 1H), 5.08 (d, J = 6 Hz, 1H), 6.69 (d, J 
= 9 Hz, 1H), 6.76 (d, J = 9 Hz, 1H).  13C NMR (CDCl3) δ 14.8, 54.7, 56.4, 57.1, 59.1, 
61.4, 74.9, 99.4, 108.3, 120.5, 124.3, 126.8, 136.0, 142.5, 142.8, 148.5, 152.3, 154.3, 
155.1.  EI-MS m/z 408 (46), 286 (100).  HRMS for C19H24N2O8 calcd 408.2498, found 
408.2484.   
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NMeO
CH3
OH
O2N
OH
OMe
OMe
 
A solution of 101 mg (0.247 mmol) of biaryl 136 in 7 mL CH2Cl2 was cooled to 0 °C, 
and 0.30 mL (0.30 mmol) of a 1M solution of BCl3 in CH2Cl2 was added dropwise, 
2
causing the evolution of gas.  After stirring at room temperature for 4 h, the reaction was 
quenched with water and extracted 3x with Et O.  The combined organic extracts were 
dried over MgSO4 and concentrated in vacuo.  Purification by column chromatography 
(3:1 hexanes:EtOAc, Rf = 0.06) and subsequent recrystallization from hexanes/Et2O gave 
11 mg (13%) of the title compound as a white, crystalline solid.  IR (CCl4) 3515 (br), 
3006 (m), 2979 (m), 2955 (m), 2936 (m), 2866 (m), 2835 (m), 1623 (m) cm-1.  1H NMR 
(CDCl3) δ 1.90 (s, 3H), 3.87 (s, 3H), 3.92 (s, 3H), 4.08 (s, 3H), 4.70 (d, J = 4 Hz, 2H), 
5.92 (s, 1H), 6.50 (d, J = 9Hz, 1H), 6.71 (d, J = 9Hz, 1H).  13C NMR (CDCl3) δ 13.2, 
54.9, 56.3, 61.6, 62.4, 104.7, 112.5, 122.9, 124.2, 135.9, 142.1, 147.1, 152.8, 153.5, 
155.4. 
 
Alcohol 138 
N
Br
NO2
OMe
OH
 
A solution of 403 mg (1.38 mmol) of methyl ether 135 in 20 mL CH2Cl2 was cooled to 0 
°C and 3.0 mL (3.0 mmol) of a 1.0 M solution of BCl3 in CH2Cl2 was added dropwise.  
The resulting solution was stirred 16 h at room temperature and quenched with water.  
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The phases were separated and the aqueous layer extracted 2x with CH2Cl2.  The 
combined organic extracts were dried over MgSO4 and concentrated in vacuo to give 383 
mg (100 %) of the title compound as a white, crystalline solid, mp 96-99 °C, which was 
used without further purification.  IR (CCl4) 3483 (br), 3026 (m), 2991 (m), 2949 (m), 
2925 (m), 2898 (m) cm .  H NMR (CDCl ) δ 2.26 (s, 3H), 3.83 (t, J = 5 Hz, 1H), 4.05 
(s, 3H), 4.70 (d, 2H, J = 5 Hz).  13C NMR (CDCl ) δ 16.0, 55.4, 62.8, 123.5, 128.9, 
153.3, 155.9. 
 
Ester 139 
-1 1
3
3
NMeO2C
Br
NO2
 
OMe
To a suspension of 397 mg (1.43 mmol) of alcohol 138 and 64 mg (1.6 mmol) NaOH in 
30 mL water was added 710 mg (4.49 mmol) KMnO4 and the resulting mixture stirred at 
room temperature for 24 h.  MeOH was added and the suspension stirred 30 min and 
filtered.  The filtrate was acidified with 1M HCl and concentrated in vacuo.  The residue 
was dissolved in 20 mL MeOH and 4 mL H2SO4, and the solution heated at reflux for 16 
h.  The solution was diluted with water and basicified with K2CO3.  The MeOH was 
removed in vacuo and the remaining aqueous solution extracted 3x with EtOAc.  The 
combined organic extracts were dried over MgSO4 and concentrated in vacuo to give 269 
mg (62%) of the title compound as a yellow, crystalline solid, mp 90-93 °C, which was 
used without further purification.  IR (CCl4) 3029 (w), 3002 (w), 2951 (m), 2924 (m), 
2850 (w), 1740 (s) cm-1.  1H NMR (CDCl3) δ 2.48 (s, 3H), 3.96 (s, 3H), 4.02 (s, 3H).  13C 
NMR (CDCl3) δ 18.5, 53.5, 55.6, 127.6, 129.6, 147.0, 153.3, 165.7.  EI-MS m/z 306 (65), 
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304 (59), 274 (89), 272 (100), 246 (58), 244 (59).  HRMS for C9H9BrN2O5 calcd 
303.9695, found 303.9683. 
 
Purification of boronic acid 113 
oronic acid was obtained using the same reaction conditions as described 
above.  After extracting with Et2O, the combined organic layers were extracted with 2 M 
KOH.  The aqueous layer was neutralized with conc HCl and extracted 3x with CH2Cl2.  
The combined organic extracts were dried over MgSO4 and concentrated in vacuo.  An 
analytical sample was obtained following recrystallization from hexanes/Et2O as a white, 
The crude b
crystalline solid, mp 125-129 °C.  IR (CCl4) 3526 (br), 3468 (br), 2998 (m), 2955 (m), 
2928 (m), 2854 (m), 2835 (m) cm-1.  1H NMR (CDCl3) δ 3.49 (s, 3H), 3.79 (s, 3H), 3.87 
(s, 3H), 5.25 (s, 2H), 6.29 (br s, 2H), 6.72 (d, J = 8 Hz, 1H), 7.52 (d, J = 8 Hz, 1H).  13C 
NMR (CDCl3) δ 56.4, 58.6, 61.1, 100.7, 108.5, 131.8, 140.8, 156.5, 156.8.  
 
 
Biaryl 140 
NMeO
O2N CH3
CO2Me
OMe
OMe  
A solution of 682 mg (2.24 mmol) of ester 139, 1.20 g (4.96 mmol) boronic acid 113, 387 
mg (0.335 mmol) Pd(PPh
OMOM
e combined organic extracts were dried over MgSO4 and concentrated in 
3)4, and 673 mg (4.43 mmol) CsF in 35 mL DME was heated at 
75 °C for 24 h.  After cooling, the solution was diluted with water and extracted 3x with 
CH2Cl2.  Th
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vacuo.  Purification by column chromatography (4:1 hexanes:EtOAc, Rf = 0.20) gave 646 
mg (68%) of the title compound as a white, crystalline solid, mp 90-93 °C.  IR (CCl4) 
3002 (m), 2948 (m), 2932 (m), 2897 (m), 2839 (m), 1740 (s) cm-1.  1H NMR (CDCl3) δ 
2.16 (s, 3H), 3.11 (s, 3H), 3.84 (s, 3H), 3.87 (s, 3H), 3.96 (s, 3H), 4.04 (s, 3H), 4.84 (d, J 
19 22 2 9
= 6 Hz, 1H), 5.10 (d, J = 6  Hz, 1H), 6.71 (d, J = 8 Hz, 1H), 6.76 (d, J = 8 Hz, 1H).  13C 
NMR (CDCl3) δ 15.9, 53.2, 55.2, 56.5, 57.2, 61.4, 99.5, 108.4, 119.6, 124.2, 127.7, 
137.6, 142.8, 143.6, 146.7, 148.5, 152.6, 155.5, 166.7.  EI-MS m/z 422 (100), 300 (32), 
272 (36).  HRMS for C H N O  calcd 422.1325, found, 422.1332.  
 
Pyridone 141 
H
O N CH
OH
OMe  
A solution of 81 mg (0.192 mmol) pyridine 140 and 0.12 mL (1.27 mmol) PBr
N
2 3
CO2Me
OMe
O
 was heated at reflux for 12 h.  After cooling, the reaction was quenched with 
ater and the mixture extracted 3x with CH2Cl2.  The combined organic extracts were 
in vacuo the residue washed with Et2O to obtain 63 mg (90%) of the title 
compound as a white solid, mp 225-235 (decomp), which was used without further 
purification.  IR (CHCl3) 3515 (br), 3344 (br), 2843 (w), 1750 (w) 1685 (s) cm-1.  1H 
NMR (CDC ) δ 2.18 (s, 3H), 3.87 (s, 3H), 3.92 (s, 3H), 3.98 (s, 3H), 6.02 (br s, 1H), 
3
3 in 4 mL 
of DCE
w
concentrated 
l3
6.51 (d, J = 9 Hz, 1H), 6.72 (d, J = 9 Hz, 1H), 10.35 (br s).  13C NMR (CDCl ) δ 15.44, 
54.1, 56.3, 61.6, 105.0, 111.6, 122.8, 123.6, 130.6, 135.9, 146.1, 146.4, 146.9, 153.7, 
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154.0, 161.5.  FAB-MS 365 (100).  HRMS for C H N O  calcd 365.0985, found 
365.0979. 
  
Triflate 142 
16 16 2 8
N
2 3
CO2Me
OH
OMe
OMe
TfO
O N CH
 
 suspension of 63 mg (0.172 mmol) of pyridone 141 and 23 mg (0.188 mmol) DMAP in 
2 was cooled to 0 °C and 35 μL (0.21 mmol) Tf2O added.  The resulting 
solution was allowed to warm to room temperature and stirred 12 h.  The reaction was 
quenched with water and the mixture extracted 3x with CH2Cl2.  The combined organic 
3
17 15 3 2 10
A
4 mL CH2Cl
extracts were dried over MgSO4 and concentrated in vacuo.  Recrystallization from 
hexanes/Et2O gave 71 mg (83%) of the title compound as a white, crystalline solid, mp 
163-165.  IR (CCl4) 3515 (br), 3010, (w), 2955 (w), 2936 (w), 2839 (w), 1740 (m) cm-1.  
1H NMR (CDCl3) δ 2.32 (s, 3H), 3.89 (s, 3H), 3.93 (s, 3H), 3.98 (s, 3H), 6.01 (br s, 1H), 
6.55 (d, J = 8 Hz, 1H), 6.72 (d, J = 8Hz, 1H).  13C NMR (CDCl ) δ 16.6, 53.7, 56.4, 61.7, 
105.1, 110.9, 123.9, 136.1, 137.8, 139.5, 143.4, 146.1, 147.1, 147.5, 154.3, 164.8.  EI-MS 
m/z 496 (98), 418 (52), 317 (100).  HRMS for C H F N O S calcd 496.0400, found 
496.0385. 
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Trinitroresorcinol 149 
OH
HO
NO2
O2N NO2
A solution of 1.16 g (10.5 mmol) of resorcinol in 5.0 mL H SO  was heated to 95 °C.  To 
°
-1 1
13
 
 
To a solution of 6.21 g (0.00564 mol) of resorcinol in 1.2 L water and 18 mL HOAc was 
added 38.2 g (0.554 mol) of NaNO2 in one portion.  The resulting solution was allowed 
 
2 4
this solution was added 4.5 mL HNO3 over 15 min, and after 75 min at 95 °C, 2 mL 
water was added and the resulting mixture filtered.  The filtrate was heated to reflux for 
30 min, causing the evolution of gas.  After cooling, the solution was neutralized with 
saturated NaHCO3 and concentrated to 100 mL.  Conc HCl was added, causing the 
formation of white precipitate, which was collected by filtration and recrystallized from 
CHCl3 to give 1.98 g (77%) of the title compound as a white, red solid, mp 173-177 C 
(decomp).  IR (CCl4) 3181 (br), 3078 (m) cm .  H NMR (DMSO-d6) δ 8.57 (s, 1 H), 
8.75 (br s, 2 H).  C NMR (DMSO-d6) 126.3, 126.6, 135.9, 156.4. 
Diol 150 
HO
OH
ON NO
to stir for 1 h during which time a precipitate formed.  The product was collected by 
filtration to yield 9.37 g (99%) of a brown solid, mp 148-149 °C (decomp), which was 
used without further purification.  Spectral data matched that of the reported 
compound.130  IR (CCl4) 3503 (br), 3383 (br), 2920 (m), 2847 (m) cm-1.  1H NMR 
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(DMSO-d6) δ 6.33 (d, J = 10 Hz, 1 H), 6.44 (d, J = 10 Hz, 1 H), 7.77 (m, 2H), 13.78 (br 
s, 2 H).  13C NMR (DMSO-d6) δ 129.3, 130.0, 130.2, 131.4, 131.8, 147.6, 147.9, 173.9, 
178.5, 179.5, 183.3.  FAB-MS m/z 169 (21), 154 (100), 136.0 (88), 107 (32), 89.0 (38), 
77 (33). HRMS for C6H4N2O4 calcd 169.0249, found 169.0249. 
 
Dinitroresorcinol 151 
HO
OH
O2N NO2
 
To a solution of 3.67 g (21.8 mol) of dinitroso diol 150 in 50 mL TFA was added 5.0 mL 
30% H2O2.  The solution was stirred at room temperature for 24 h and 
concentrated in vacuo.  The residue was recrystallized from CHCl3 to yield 3.85 g (88%) 
of the title compound as a white, crystalline solid, mp 145-146 °C.  IR (KBr) 3433 (br) 
3216 (br), 3099 (w), 2920 (w), 2850 (w) cm-1.  1H NMR (CDCl3) δ 6.76 (d, J = 8 Hz, 1 
H), 8.31 (d, J = 8 Hz, 1 H), 11.31 (br s, 1 H), 12.61 (s, 1 H).  13C NMR (DMSO-d ) δ 
109.5, 128.7, 129.1, 132.2, 148.5, 157.4.  EI-MS m/z 200 (94), 96 (100), 80 (47).  HR-
MS for C H N O  calcd 200.0069, found 200.0064. 
 
Dimethoxy arene 152 
(44 mmol) of 
  6
6 4 2 6
MeO
OMe  
To a solution of 2.92 g (14.6 mmol) of diol 151 in 125 mL acetone was added 7.38 g 
O2N NO2
(53.4 mmol) of K CO .  To this mixture was added 4.5 mL (45 mmol) of dimethyl 
sulfate, and the resulting mixture heated at reflux for 16 h.  After cooling, the mixture 
2 3
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was concentrated in vacuo and the residue dissolved in Et2O.  The organic phase was 
washed 2x with 2M KOH, dried over MgSO4, and concentrated in vacuo.  
ecrystallization from hexanes/Et2O afforded 2.35 g (71%) of the title compound as a 
line solid, mp 72-73 °C.  IR (CCl4) 3107 (w), 3021 (w), 2983 (m), 2940 
(m), 2639 (m), 1616 (s) cm-1.   1H NMR (CDCl3) δ 3.99 (s, 3H), 4.00 (s, 3H), 6.86 (d, J = 
10 Hz, 1H), 8.16 (d, J = 10 Hz, 1H).  13C NMR (CDCl3) δ 57.7, 65.1, 107.6, 129.1, 136.5, 
138.0, 148.8, 155.9.  EI-MS m/z 228 (100), 198 (32).  HRMS for C8H8N2O6 calcd 
R
white, crystal
228.0382, found 228.0394.   
 
Phenol 153 or 154 
 
O2N
OH
MeO
OR
OMe
HO
 
 
A solution of 67 mg (0.29 mmol) of dinitroarene 152 in 1.5 mL MeOH was heated to 60 
°C.  To the solution was added 165 mg (2.94 mmol) of NaHS in 6 mL MeOH and the 
resulting solution heated at 80 °C for 2.5 h.  After cooling, the solution was neutralized 
with conc HCl and concentrated in vacuo.  Water was added to the residue and precipitate 
obtained by filtration to yield 45 mg (71%) as orange solid, mp 102-106 °C.  IR (CCl
NO2 O2N NO2
H), 8.25 (d, J = 8 Hz, 1H), 11.05 (s, 1H).  13C NMR (CDCl3) δ 57.8, 104.3, 
128.5, 128.6, 131.5, 149.4, 158.2. 
4) 
3161 (br), 2979 (w), 2944 (w), 2847 (w) cm-1.  1H NMR (CDCl3) δ 4.02 (s, 3H), 6.68 (d, 
J = 8 Hz, 1
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Nitroamine 155a or 155b 
O2N
OMe
NH2
MeO
OR
H2N
OMe
NO2
MeO
 
H  was bubbled through a suspension of 2.21 g (10.0 mmol) of dinitroarene 154 and 117 
mg of 10% Pd/C in 100 mL THF.  After 24 h, analysis by TLC indicated the starting 
material was consumed.  The mixture was filtered through celite and the filtrate 
concentrated in vacuo to give 1.80 g (95%) of a single compound as an orange oil.  IR 
(CCl4) 3383 (br), 2924 (m), 2850 (m) cm .  H NMR (CDCl3) δ 3.65 (br s, 2H), 3.79 (s, 
3H), 3.84 (s, 3H), 6.62 (d, J = 9 Hz, 1H), 6.76 (d, J = 9 Hz, 1H).  C NMR (CDCl ) δ 
57.4, 61.9, 109.3, 117.6, 134.7, 139.8, 144.2, 
 
Diamine 156 
2
-1 1
13
3
NH2
MeO
H2N
 
H2 was bubbled through a mixture of 800 mg of 10% Pd/C, 2.76 g (12.1 mmol) of dinitro 
, and 100 mL THF.  The reaction was minotored by TLC until only a single 
ompound remained and the mixture filtered through celite.  The filtrate concentrated in 
3
c
OMe
arene 154
c
vacuo to yield 2.03 g (100%) of diamine 156 as an orange oil, which was used without 
further purification.  IR (CCl4) 3460 (m), 3375 (m), 3041 (w), 2998 (m), 2936 (m), 2905 
(m), 2827 (m), 1612 (m) cm-1.  1H NMR (CDCl3) δ 3.58 (br s, 4H), 3.76 (s, 6 H), 6.09 (d, 
J = 9 Hz, 1H), 6.43 (d, J = 9 Hz, 1H).  13C NMR (CDCl ) δ 56.7, 58.9, 104.0, 107.8, 
130.7, 134.3, 135.9, 141.6.  EI-MS m/z 168 (58), 153 (100), 138 (56).  HRMS for 
C8H12N2O2 alcd 168.0899, found 168.0902.  
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Bis-pivalanilide 157 
NHPiv
OMe
PivHN
MeO
 
To a suspension of 598 mg (3.56 mmol) of diamine 156 and 6.6 g (48 mmol) K2CO3 in 
0 mL THF was added 5.5 mL (45 mmol) of pivaloyl chloride, causing the immediate 
recipitate.  The resulting suspension was heated a reflux for 90 
min.  After cooling, the reaction was quenched with water and the solution extracted 3x 
with Et2O.  The combined organic extracts were dried over MgSO4 and concentrated in 
4
formation of a white p
vacuo.  Purification by column chromatography (1:1 hexanes:EtOAc, Rf = 0.15) yielded 
925 mg (77%) of the title compound as a white, crystalline solid, mp 123-126 °C.  IR 
(CCl4) 3449 (m), 2963 (m), 2905 (m), 2866 (m), 2835 (m), 1693 (s) cm-1.  1H NMR 
(CDCl3) δ 1.28 (s, 9H), 1.36 (s, 9H), 3.72 (s, 3H), 3.77 (s, 3H), 6.63 (d, J = 8 Hz, 1H), 
6.95 (br s, 1H), 7.94 (br s, 1 H), 8.15 (d, J = 8 Hz, 1H).  13C NMR (CDCl3) δ 15.7, 28.0, 
28.1, 39.9, 40.2, 56.6, 60.7, 66.3, 106.8, 119.0, 119.1, 126.0, 146.2, 151.0, 176.9, 177.4.  
FAB-MS m/z 337 (100), 336 (64),, 253 (62), 57 (67).  HRMS for C18H28N2O4 calcd 
337.2127, found 337.2137. 
 
Bromide 158 
OMe
MeO
PivHN NHPiv
Br
 
To a solution of 105 mg (0.312 mmol) of bis-pivalanilide 157 in 4 mL HOAc was added 
a solution of 0.020 mL (0.39 mmol) Br  in 5 mL HOAc.  The resulting solution was 
stirred 24 h at room temperature, quenched with aqueous Na S O , and extracted 2x with 
2
2 2 3
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Et2O.  The combined organic extracts were dried over MgSO4 and concentrated in vacuo 
to afford 124 mg (95%) of the title compound as a white, crystalline solid, mp 140-143 
°C.  IR (CCl4) 3441 (m), 3309 (br), 2963 (m), 2924 (m), 2850 (m), 1697 (m) cm-1.  1H 
NMR (CDCl3) δ 1.31 (s, 9H), 1.33 (s, 9H), 3.65 (s, 3H), 3.78 (s, 3H), 6.87 (br s, 1H), 
6.91 (s, 1H), 6.97 (br s, 1H).  13C NMR (CDCl3) δ 28.0, 28.1, 39.7, 39.8, 56.8, 61.2, 
111.3, 120.0, 121.6, 123.7, 153.9, 154.8, 177.5, 177.6. 
 
Diaminobromide 159 
H3CO Br
To a solution of 0.10 mL (0.59 mmol) of a 48% solution of HBr in water and 0.10 mL 
DMSO in 3 mL CH2Cl2 was added a solution of 0.046 mg (0.27 mmol) of amine 159 in 3 
H2N
OCH3
NH2
 
mL CH2Cl2.  The resultant solution was stirred for 3 d, diluted with water, and basicified 
with K2CO3.  The solution was extracted 3x with CH2Cl2, and the combined organic 
extracts dried over MgSO4 and concentrated in vacuo.  Purification by column 
chromatography (3:1 hexanes:EtOAc, Rf = 0.22) gave 25 mg (37%) of the title compound 
as yellow, crystalline solid, mp 144-148 °C (decomp).  IR (CCl4) 3476 (m), 3379 (m), 
3002 (m), 2967 (m), 2944 (m) cm-1.  1H NMR (CDCl3) δ 3.68 (br s, 4H), 3.75 (s, 6 H), 
6.66 (s, 1H).  13C NMR (CDCl3) δ 56.7, 58.8, 96.3, 110.9, 130.1, 133.0, 135.6, 141.5.  
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Bromobis-pivalanilide 158 
OMe
MeO
PivHN NHPiv
Br
 
This compound was obtained in 72% yield according to the same procedure as bis-
pivalanilide 158, as a white, crystalline solid.  IR (CCl4) 3441 (w), 3309 (br), 2963 (m), 
2924 (m), 2850 (m), 1697 (m) cm-1.  1H NMR (CDCl3) δ 1.31 (s, 9H), 1.33 (s, 9H), 3.65 
(s, 3H), 3.78 (s, 3H), 6.87 (br s, 1H), 6.91 (s, 1H), 6.97 (br s, 1H).  13C NMR (CDCl3) δ 
28.0, 28.1, 39.7, 39.8, 56.8, 61.2, 111.3, 120.0, 121.6, 123.7, 153.9, 154.8, 177.5, 177.6. 
 
Biaryl 163 
N
NHAc  
A solution of 39 mg (0.14 mmol) triflate 118, 140 mg (0.473 mmol) stannane 161,139 and 
41 mg (0.97 mmol) LiCl was stirred at room temperature for 30 min.  To the solution was 
added 29 mg (0.025 mmol) of Pd(PPh3)4 and the resulting solution heated at reflux for 20 
h.  After cooling, saturated NH4Cl was added and the product extracted 3x with Et2O.  
The combined organic extracts were dried over MgSO4 and concentrated in vacuo.  
Purification by column chromatography (1:1 EtOAc:hexanes, Rf = 0.40) yielded 13 mg 
(36%) of the title compound as a white, crystalline solid, mp 155-160 °C.  IR (CCl4) 3445 
(w), 2967 (m), 2920 (s), 2854 (m), 1709 (s) cm-1.  1H NMR (CDCl3) δ 2.19 (s, 3H), 7.44 
(br s, 1H), 7.50 (t, J = 8 Hz, 1H), 7.65-7.72 (m, 3H), 7.79-7.84 (m, 2H), 8.12-8.20 (m, 4 
H).  FAB-MS m/z 263 (H+, 62), 262 (14), 154 (70), 136 (70).  HRMS for C18H14N2O 
calcd 262.1106, found 262.1103. 
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Amidoolefin 166 
NHPiv  
A solution of 240 mg (1.00 mmol) allyic benzoate 165,46 353 mg (1.08 mmol) siloxane 
164,  and 87 mg (0.16 mmol) Pd(dba)  in 15 mL THF was degassed via a single freeze-
pump-thaw cycle.  TBAF (1.15 mL of a 1M solution in THF, 1.15 mmol) was added and 
the resulting solution degassed via a second freeze-pump-thaw cycle.  The solution was 
heated at 60 °C for 24 h, diluted with water, and extracted 3x with Et O.  The combined 
organic extracts were dried over MgSO  and concentrated in vacuo.  Purification by 
column chromatography (9:1 hexanes:EtOAc, R  = 0.14) gave 134 mg (45%) of the title 
compound as a white, crystalline solid, mp 96-99 °C.  IR (CCl ) 3425 (br), 3091 (w), 
3060 (w), 3021 (w), 2959 (m), 2924 (m), 2870 (w), 1693 (s) cm-1.  1H NMR (CDCl ) δ 
1.24 (s, 9H), 3.53 (d, 2H, J = 5 Hz), 6.31 (dt, J = 16 Hz, 5 Hz, 1H), 6.42 (d, J = 16 Hz, 
1H), 7.10 (dt, J = 8 Hz, 1 Hz, 1H), 7.21-7.32 (m, 7H), 7.48 (br s, 1H), 7.95 (d, J = 8 Hz, 
1H).  13C NMR (CDCl ) δ 28.1, 36.5, 40.1, 123.8, 125.4, 126.6, 127.8, 128.1, 129.1, 
130.3, 130.6, 132.3, 136.8, 137.0, 177.0.  
 
Dibromide 168 
43
2
2
4
f
4
3
3
NH
Br
Br
Piv  
A solution of 0.050 mg (0.17 mmol) of alkene 166 in 3 mL CH2Cl2 was cooled to 0 C.  
To this solution was added a dropwise a solution of 7 drops of Br
°
2 in 3 mL CH2Cl2 and 
the resulting solution allowed to warm to room temperature and stirred 16 h.  Water was 
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added and the solution extracted 2x with CH2Cl2.  The combined organic extracts were 
dried over MgSO4 and concentrated in vacuo.  Purification by column chromatography 
(9:1 hexanes:EtOAc, Rf = 0.10) afforded 37 mg (48%) of the title compound as a white, 
crystalline solid, mp 159-160 °C (decomp).  IR (CCl4) 3433 (br), 2955 (m), 2920 (m), 
2854 (m), 1685 (s) cm-1.  1H NMR (CDCl3) δ 1.32 (s, 9H), 3.16 (dd, J = 15 Hz, 10 Hz, 
1H), 3.85 (dd, J = 15 Hz, 2 Hz, 1H), 4.67 (dt, J = 10 Hz, 2 Hz, 1H), 5.18 (d, J = 10 Hz, 
H), 7.18 (dt, J = 8 Hz, 1Hz, 1H), 7.27-7.40 (m, 7H), 7.62 (d, J = 8 Hz, 1H), 7.67 (br s, 
) δ 28.2, 38.8, 40.0, 57.8, 60.1, 126.4, 128.3, 128.4, 129.2, 129.5, 
131.0, 131.3, 136.2, 139.9, 177.6.  FAB-MS m/z 456 (78), 454 (94), 452 (52), 294 (100), 
292 (86).  HRMS for C20H23Br2NO calcd 454.0204, found 454.0220.  
1
1H).  13C NMR (CDCl3
 
Carbamate 170 
NHBOC  
To a solution of 114 mg (0.478 mmol) of allylic benzoate 165, 202 mg (0.595 mmol) 
siloxane 169, and 109 mg (0.199 mmol) Pd(dba)2 in 10 mL THF was added 0.60 mL 
(0.60 mmol) of a 1M solution of TBAF in THF.  The solution was degassed via a single 
freeze-pump-thaw cycle and heated at 60 °C for 24 h.  After cooling, the solution was 
diluted with water and extracted 3x with Et2O.  The combined organic extracts were dried 
4
tOAc, Rf = 0.34) afforded 79 mg (56%) of title compound as a white, 
crystalline solid, mp 104-107 °C.  IR (CCl4) 3441 (br), 3021 (w), 2979 (w), 1740 (s) cm-
1.  1H NMR (CDCl3) δ 1.46 (s, 9H), 3.50 (d, J = 6 Hz, 2H), 6.30 (dt, J = 16 Hz, 6 Hz, 
over MgSO  and concentrated in vacuo.  Purification by column chromatography (9:1 
hexanes:E
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1H), 6.42 (d, J = 16 Hz, 1H), 6.45 (br s, 1H), 7.05 (t, J = 8 Hz, 1H), 7.17-7.34 (m, 7H), 
7.77 (d, J = 8 Hz, 1H).  EI-MS m/z 310 (5), 253 (100), 118 (58).  HRMS for C20H21NO2 
calcd 309.1729, found 309.1728. 
 
Amino olefin 171 
NH2  
A solution of 79 mg (0.27 mmol) of carbamate 170 dissolved in 4 mL of 3M HCl and 10 
mL EtOAc was stirred at room temperature for 18 h.  The reaction was neutralized with 
saturated Na2CO3 and the product extracted 3x with EtOAc.  The combined organic 
extracts were dried over MgSO4 and concentrated in vacuo.  The residue was purified 
after passing through a plug of silica gel using pentane as the eluent to yield 38 mg (69%) 
of the title compound as a colorless oil.  IR (CCl4) 3460 (br), 3390 (br), 3087 (m), 3060 
 
(m), 3029 (m), 1619 (s) cm-1.  1H NMR (CDCl3) δ 3.46 (d, J = 6 Hz, 2H), 3.68 (br s, 2H), 
6.34 (dt, J = 16 Hz, 6 Hz, 1H), 6.46 (d, J = 16 Hz, 1H), 6.69 (d, J = 8 Hz, 1H), 6.76 (t, J = 
7 Hz, 1H), 7.09 (t, J = 8 Hz, 2H), 7.20 (t, J = 7 Hz, 1H), 7.28 (t, J = 8 Hz, 2H), 7.34 (d, J 
= 7 Hz, 2H).  13C NMR (CDCl3) δ 36.1, 116.3, 119.3, 124.6, 126.6, 127.7, 128.1, 128.2, 
129.0, 130.7, 131.6, 137.6, 145.3.  EI-MS m/z 209 (99), 118 (100).  HRMS for C15H15N 
calcd 209.1204, found 209.1201. 
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